

PHARMADRUG INC.

NOTICE TO READER

Please be advised that changes were made to the Company's annual consolidated financial statements for the year ended December 31, 2020, to correct an overstated balance of deferred tax liabilities by \$341,957, an overstated current tax recovery of \$389,075 and an understated deferred tax recovery by \$475,012, which caused the net loss and comprehensive loss for the year ended December 31, 2020 to be misstated, and an understated cash flows used in operating activities of \$389,075, which also caused the increase in cash to be misstated. Diluted earnings per share was also corrected to reflect the same amount as basic earnings per share as the result of any dilutive securities would have been anti-dilutive. As a result of the corrections, certain balances on the consolidated statement of financial position as at December 31, 2020, and the consolidated statement of loss and comprehensive loss, changes in shareholders' equity and cash flows for the year ended December 31, 2020 were also affected.

Details of the corrections are fully described in Note 2 to the Company's Amended and Restated Consolidated Financial Statements as filed on SEDAR on May 28, 2021.

The previously filed consolidated financial statements and management's discussion and analysis for the financial period in question were originally filed by the Company on SEDAR on April 30, 2021. Each of the Amended and Restated Consolidated Financial Statements and Revised Management's Discussion and Analysis replaces and supersedes the respective previously filed original consolidated financial statements and related management's discussion and analysis. There have been no other changes.



PHARMADRUG INC.

AMENDED AND RESTATED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

(EXPRESSED IN CANADIAN DOLLARS)

To the Shareholders of Pharmadrug Inc. :

Opinion

We have audited the amended and restated consolidated financial statements of Pharmadrug Inc. and its subsidiaries (the "Company"), which comprise the amended and restated consolidated statements of financial position as at December 31, 2020 and December 31, 2019, and the amended and restated consolidated statements of loss and comprehensive loss, changes in shareholders' equity and cash flows for the years then ended, and notes to the amended and restated consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying amended and restated consolidated financial statements present fairly, in all material respects, the amended and restated consolidated financial position of the Company as at December 31, 2020 and December 31, 2019, and its amended and restated consolidated financial performance and its amended and restated consolidated cash flows for the years then ended in accordance with International Financial Reporting Standards.

Basis for Opinion

We conducted our audits in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Amended and Restated Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audits of the amended and restated consolidated financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 in the amended and restated consolidated financial statements, which indicates that the Company has accumulated a deficit since its inception and, during the year ended December 31, 2020, incurred a net loss and negative cash flows from operations. As stated in Note 1, these events or conditions, along with other matters as set forth in Note 1, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Emphasis of Matter - Restatement

We draw attention to Note 2 to the amended and restated consolidated financial statements, which describes that the consolidated financial statements for the year ended December 31, 2020 have been restated from those on which we originally reported on April 30, 2021. Our opinion is not modified in respect of this matter.

Other Information

Management is responsible for the other information. The other information comprises Management's Discussion and Analysis.

Our opinion on the amended and restated consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audits of the amended and restated consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the amended and restated consolidated financial statements or our knowledge obtained in the audits or otherwise appears to be materially misstated. We obtained Management's Discussion and Analysis prior to the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Amended and Restated Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the amended and restated consolidated financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of amended and restated consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the amended and restated consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Amended and Restated Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the amended and restated consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these amended and restated consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the amended and restated consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the amended and restated consolidated financial statements, including the disclosures, and whether the amended and restated consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the amended and restated consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audits and significant audit findings, including any significant deficiencies in internal control that we identify during our audits.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The engagement partner on the audit resulting in this independent auditor's report is Jo-Ann Lempert.

Montréal, Québec

May 28, 2021

MNP SENCRL, s.r.l. ¹

¹ FCPA auditor, FCA, public accountancy permit no. A122514

PHARMADRUG INC.

Amended and Restated Consolidated Statements of Financial Position
(Expressed in Canadian Dollars)

	Notes	As at December 31, 2020 \$	As at December 31, 2019 \$
Assets			
Current Assets			
Cash		2,134,866	73,677
Other receivables	6	183,694	46,023
Inventories	7	39,902	110,477
Prepaid expenses	8	57,804	71,071
Note receivable	9	-	39,686
Other investments	10	2,269,504	440,052
Total Current Assets		4,685,770	780,986
Property and equipment	11	122,013	111,007
Intangible assets	12	4,291,733	5,198,779
Goodwill	12	4,589,084	4,287,713
Total Assets		13,688,600	10,378,485
Liabilities			
Current Liabilities			
Accounts payable and accrued liabilities	13	562,130	1,133,449
Loans payable	14	-	1,889,819
Notes payable	15	-	733,161
Lease liabilities – current	16	57,173	40,159
Convertible debentures – current	17	-	404,431
Income tax payable		-	119,073
Total Current Liabilities		619,303	4,320,092
Lease liabilities	16	35,581	54,284
Convertible debentures	17	1,033,082	-
Provisions	27	91,270	76,550
Deferred tax liabilities	24	996,415	1,469,461
Total Liabilities		2,775,651	5,920,387
Shareholders' Equity			
Share capital	18	21,831,792	13,215,765
Equity component of convertible debentures		248,945	63,491
Reserve for share-based payments	19	813,256	240,498
Reserve for warrants	20	2,866,900	1,656,243
Accumulated other comprehensive loss		(246,952)	(715,349)
Accumulated deficit		(15,856,884)	(11,482,682)
Equity Attributable to Shareholders of Pharmadrug Inc.		9,657,057	2,977,966
Non-Controlling Interest	5,23	1,255,892	1,480,132
Total Equity		10,912,949	4,458,098
Total Liabilities and Shareholders' Equity		13,688,600	10,378,485
Nature of operations and going concern	1		
Contingencies	27		
Commitments	28		
Subsequent events	31		

Approved on behalf of the Board of Directors:

“Daniel Cohen” (signed)
Director

“Al Quong” (signed)
Director

The accompanying notes are an integral part of these consolidated financial statements

PHARMADRUG INC.

Amended and Restated Consolidated Statements of Loss and Comprehensive Loss
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

	Notes	2020 \$	2019 \$
Revenue			
Sales revenue		683,671	610,576
Cost of goods sold	7	(501,634)	(357,321)
Gross Profit		182,037	253,255
Expenses			
Salaries and consulting fees	22	643,343	667,992
Professional fees	22	1,174,390	1,642,663
Office and general		211,221	175,997
Depreciation on office equipment	11	41,500	26,529
Depreciation on right-of-use assets	11	7,891	-
Amortization on intangible assets	12	1,247,183	751,701
Filing fees		39,641	52,672
Travel and promotion		33,478	328,699
Share-based compensation	19	774,815	527,662
Reversal (allowance) on expected credit losses	25	(152,710)	1,172,935
		(4,020,752)	(5,346,850)
Loss before Other Expenses		(3,838,715)	(5,093,595)
Other Expenses			
Unidentifiable assets acquired	5	(4,509,267)	-
Gain on sale of investments in joint venture	9	-	46,616
Loss on share exchange transaction	10	(40,801)	-
Realized loss on disposals of investments	10	(42,611)	(1,625,285)
Fair value change in investments	10	2,574,778	440,052
Finance costs	30	(321,293)	(476,986)
Fair value change in derivative liability	17(a)	-	(166,243)
Gain on settlement	9,14,17(d),18(p)	169,279	-
Other expenses		(9,108)	-
Foreign exchange gain (loss)		115,111	(106,382)
		(2,063,912)	(1,888,228)
Net Loss before Income Taxes		(5,902,627)	(6,981,823)
Deferred tax recovery	24	475,012	442,748
Net Loss		(5,427,615)	(6,539,075)
Other Comprehensive Loss			
Exchange gain (loss) on translation of foreign operations		521,491	(662,953)
Net Loss and Comprehensive Loss		(4,906,124)	(7,202,028)
Total Net Loss Attributable to:			
Shareholders of Pharmadrug Inc.		(5,150,281)	(6,289,836)
Non-Controlling Interest	23	(277,334)	(249,239)
Net Loss		(5,427,615)	(6,539,075)
Net Loss per Share			
Basic and diluted	21	(0.038)	(0.093)
Weighted Average Number of Outstanding Shares			
Basic and diluted	21	142,456,439	70,113,432

The accompanying notes are an integral part of these consolidated financial statements

PHARMADRUG INC.

Amended and Restated Consolidated Statements of Cash Flows
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

	Notes	2020 \$	2019 \$
<u>Operating Activities</u>			
Net loss for the year		(5,427,615)	(6,539,075)
Adjustments for non-cash items:			
Share-based compensation	19	774,815	527,662
Depreciation on office equipment	11	41,500	26,529
Depreciation on right-of-use assets	11	7,891	-
Amortization on intangible assets	12	1,247,183	751,701
(Reversal) allowance on expected credit loss	25	(152,710)	1,172,935
Unidentifiable assets acquired	5	4,509,267	-
Realized loss on disposals of investments	10	42,611	1,625,285
Fair value change on investments	10	(2,574,778)	(440,052)
Restructuring fees		467,726	-
Loss on share exchange transaction	10	40,801	-
Finance costs	14,15,17	225,116	476,986
Fair value change in derivative liability	17(a)	-	166,243
Gain on sale of investments in joint venture		-	(46,616)
Gain on settlements	9,14,17	(169,279)	-
Deferred tax recovery	24	(475,012)	(442,748)
Other expenses (income)		6,660	(6,356)
Foreign exchange gain		(115,111)	(7,392)
		(1,550,935)	(2,734,898)
Net change in non-cash working capital items:			
Other receivables	6	(140,033)	(115,176)
Inventories	7	77,289	(95,150)
Prepaid expenses	8	14,712	48,564
Accounts payable and accrued liabilities	13	(88,416)	591,383
Provisions		9,346	75,046
Income tax payable	24	(124,945)	(109,738)
Cash Flows (used in) Operating Activities		(1,802,982)	(2,339,969)
<u>Financing Activities</u>			
Proceeds from private placement financings	18	200,000	1,724,100
Share issue costs	18	-	(38,353)
Proceeds received on subscription receipts financings	18	-	4,740,000
Commissions paid on subscription receipts financings	18	-	(487,616)
Interest payment made on debentures		(62,135)	(72,000)
(Repayment) proceeds from Bridge Loan Facility	14	(1,889,819)	3,000,000
Proceeds received on loan from third party	14	250,000	-
Repayment on loan from third-party	14	(250,000)	-
Proceeds from advances from Super Smart	14	480,000	-
Proceeds from notes payable	15	-	600,000
Lease payments	16	(52,349)	(20,298)
Proceeds from exercise of options	18	-	26,000
Proceeds from exercise of warrants	18	1,429,946	38,119
Proceeds from exercise of broker options	18	26,592	-
Cash Flows provided by Financing Activities		132,235	9,509,952

The accompanying notes are an integral part of these consolidated financial statements

PHARMADRUG INC.

Amended and Restated Consolidated Statements of Cash Flows
 For the Years Ended December 31, 2020 and 2019
 (Expressed in Canadian Dollars)

	Notes	2020	2019
		\$	\$
<u>Investing Activities</u>			
Acquisition of Pharmadrug GmBH	5	-	(7,101,848)
Cash (paid) acquired on business acquisitions	5	(15,805)	16,978
Cash acquired on amalgamation with Interrobang	5	2,191,932	-
Payment received on note receivable	9	-	15,313
Advances made to acquisition targets		-	(230,135)
Payments on exercise of warrant investments	10	(492,076)	-
Proceeds from disposals of investments	10	2,115,332	-
Purchases of property and equipment	11	(17,966)	(9,787)
Additions of intangible assets	12	-	(9,258)
Cash Flows provided by (used in) Investing Activities		3,781,417	(7,318,737)
Increase (decrease) in cash		2,110,670	(148,754)
Effects of foreign exchange on cash		(49,481)	67,314
Cash, beginning of year		73,677	155,117
Cash, end of year		2,134,866	73,677
<u>Supplemental Information</u>			
Bridge Loan Facility settled with proceeds on sale of other investments	10,14	741,375	1,374,715
Bridge Loan Facility settled with issuance of units	14,18	478,301	-
Interest expense on lease payable	16	1,967	1,042
Debts settled with issuance of units	13,18	721,854	-
Debts settled through conversion of new debts	15,17	1,005,619	-

The accompanying notes are an integral part of these consolidated financial statements

PHARMADRUG INC.

Amended and Restated Consolidated Statements of Changes in Shareholders' Equity
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

	Notes	Share Capital		Reserves				Accumulated Other Comprehensive Loss	Accumulated Deficit	Non- Controlling Interest	Total
		Number of Shares	Amount	Shares to be Issued	Equity Component of Debentures	Reserve for Share-Based Payments	Reserve for Warrants				
		#	\$	\$	\$	\$	\$				
Balance, December 31, 2018		31,072,567	3,899,096	6,356	63,491	170,078	673,058	(52,395)	(5,250,004)	-	(490,320)
Units and warrants issued on private placements	18,20	33,039,452	5,558,496	-	-	-	905,604	-	-	-	4,644,100
Broker warrants issued on private placements	20	-	-	-	-	-	496,022	-	-	-	496,022
Share issue costs	18,20	-	(452,425)	-	-	-	(382,405)	-	-	-	(834,830)
Issuance on conversion of debentures	17,18	4,000,000	897,520	-	-	-	-	-	-	-	897,520
Issuance on share exchange agreement	10,18	14,376,130	3,187,161	-	-	-	-	-	-	-	3,187,161
Shares issued for services	18	300,000	37,500	-	-	-	-	-	-	-	37,500
Share-based compensation	19	-	-	-	-	115,840	-	-	-	-	115,840
Exercise of options	18,19	260,000	39,000	-	-	(13,000)	-	-	-	-	26,000
Expiry of options	19	-	-	-	-	(32,420)	-	-	32,420	-	-
Exercise of warrants	18,20	254,125	49,417	-	-	-	(11,298)	-	-	-	38,119
Expiry of warrants	20	-	-	-	-	-	(24,738)	-	24,738	-	-
NCI acquired on business combination	5	-	-	-	-	-	-	-	-	1,729,371	1,729,371
Reversal of shares to be issued	-	-	-	(6,356)	-	-	-	-	-	-	(6,356)
Exchange loss on translating foreign operations	-	-	-	-	-	-	-	(662,954)	-	-	(662,954)
Net loss for the year	-	-	-	-	-	-	-	-	(6,289,836)	(249,239)	(6,539,075)
Balance, December 31, 2019		83,302,274	13,215,765	-	63,491	240,498	1,656,243	(715,349)	(11,482,682)	1,480,132	4,458,098
Issuance on amalgamation transaction	5	44,400,000	2,886,000	-	-	-	1,749,765	-	-	-	4,635,765
Issuance on conversion of debentures	17,18	46,996,045	1,742,366	-	-	-	616,386	-	-	-	2,358,752
Units and warrants issued on private placements	18,20	2,666,667	110,494	-	-	-	89,506	-	-	-	200,000
Issuance on debt settlements	13,15,16,18	24,003,104	952,155	-	185,454	-	197,607	-	-	-	1,335,216
Issuance on share exchange agreement	10,18	9,333,333	336,420	-	-	-	263,469	-	-	-	599,889
Shares issued for services	18,21	1,800,000	63,000	-	-	-	-	-	-	-	63,000
Share-based compensation	19	-	-	-	-	711,815	-	-	-	-	711,815
Expiry and cancellation of options	19	-	-	-	-	(139,057)	-	-	139,057	-	-
Exercise of warrants	18,20	28,598,920	2,483,997	-	-	-	(1,054,051)	-	-	-	1,429,946
Exercise of broker options	18,20	531,840	41,595	-	-	-	(29,527)	-	-	-	12,068
Issuance on exercise of broker options	20	-	-	-	-	-	14,524	-	-	-	14,524
Expiry of warrants	20	-	-	-	-	-	(637,022)	-	637,022	-	-
Exchange gain on translating foreign operations	-	-	-	-	-	-	-	468,397	-	53,094	521,491
Net loss for the year	-	-	-	-	-	-	-	-	(5,150,281)	(277,334)	(5,427,615)
Balance, December 31, 2020		241,632,183	21,831,792	-	248,945	813,256	2,866,900	(246,952)	(15,856,884)	1,255,892	10,912,949

The accompanying notes are an integral part of these consolidated financial statements

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

1. Nature of Operations and Going Concern

Pharmadrug Inc. (“Pharmadrug” or the “Company”) is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally derived approved drugs. The Company owns an 80% equity in Pharmadrug Production GmbH (“Pharmadrug GmbH”), a medical cannabis distributor in Germany with a Schedule I European Union (“E.U.”) narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the E.U. The Company also owns and operates an early-stage retail company focused on consolidating the psychedelic smartshop market in the Netherlands. The address of the Company’s registered office is 77 King Street West, Suite 2905, Toronto, Ontario, M5K 1H1, Canada.

The Company’s common shares are listed on the Canadian Securities Exchange under the trading symbol “BUZZ”. The Company’s shares are also traded in the United States (the “U.S.”) on the Pink Open Market under the ticker symbol “LMLLF”.

The business of medical cannabis and psychedelics involves a high degree of risk, and there is no assurance that any prospective projects in the medical cannabis industry and psychedelic domain will be successfully initiated or implemented. Further, regulatory evolution and uncertainty may require the Company to alter its business plan to react to regulatory changes.

For the year ended December 31, 2020, the Company incurred a net loss of \$5,427,615 and negative cash flow from operations of \$1,802,982, and as at December 31, 2020, the Company had an accumulated deficit of \$15,856,884 (December 31, 2019 – deficit of \$11,482,682). The Company’s ability to continue as a going concern is dependent upon the Company achieving profitable operations to generate sufficient cash flows to fund continuing operations, or, in the absence of adequate cash flows from operations, obtaining additional financing to support operations for the foreseeable future. It is not possible to predict whether financing efforts will be successful or if the Company will attain profitable levels of operations. The unpredictability of the medical cannabis and psychedelic business, and the continued evolution of the coronavirus (“COVID-19”) pandemic represent material uncertainties which may cast significant doubt upon the Company’s ability to continue as a going concern.

These consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, and do not reflect the adjustments to the carrying values of assets and liabilities and the reported revenues and expenses, and classifications of statements of financial position that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material.

2. Restatement of Previously Reported Consolidated Financial Statements

Subsequent to the issuance of the previously reported consolidated financial statements for the year ended December 31, 2020 (filed on SEDAR on April 30, 2021), it was determined that the balance of the deferred tax liabilities was overstated by \$341,957, an overstated current tax recovery by \$389,075 and an understated deferred tax recovery by \$475,012, which caused the total liabilities, the accumulated deficit and the net loss, as at and for the year ended December 31, 2020 to be misstated. Diluted earnings per share was also corrected to reflect the same amount as basic earnings per share as the result of any dilutive securities would have been anti-dilutive.

As a result of the corrections, certain balances on the consolidated statement of financial position as at December 31, 2020, and the consolidated statement of loss and comprehensive loss, changes in shareholders’ equity and cash flows for the year ended December 31, 2020 were also affected.

The following tables summarize the effects of the adjustments.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

2. Restatement of Previously Reported Consolidated Financial Statements (continued)

Line items on the amended and restated consolidated statement of financial position and amended and restated consolidated statement of changes in shareholders' equity:

	Previously reported	Adjustments	Restated
	\$	\$	\$
Deferred tax liabilities	1,338,372	(341,957)	996,415
Total Liabilities	3,117,608	(341,957)	2,775,651
Accumulated other comprehensive loss	(502,972)	256,020	(246,952)
Accumulated deficit	(15,925,634)	68,750	(15,856,884)
Equity attributable to Shareholders of Pharmadrug Inc.	9,332,287	324,770	9,657,057
Non-Controlling Interest	1,238,705	17,187	1,255,892
Total Equity	10,570,992	341,957	10,912,949

Line items on the amended and restated consolidated statement of loss and comprehensive loss:

	Previously reported	Adjustments	Restated
	\$	\$	\$
Current tax recovery	389,075	(389,075)	-
Deferred tax recovery	-	475,012	475,012
Net Loss	(5,513,552)	85,937	(5,427,615)
Exchange gain (loss) on translation of foreign operations	265,471	256,020	521,491
Net Loss and Comprehensive Loss	(5,248,083)	341,959	(4,906,124)
Total Net Loss attributable to Shareholders of Pharmadrug Inc.	(5,219,031)	68,750	(5,150,281)
Total Net Loss attributable to Non-Controlling Interest	(294,521)	17,187	(277,334)
Net Loss per Share – Basic	(0.039)	0.001	(0.038)
Net Loss per Share – Diluted	(0.031)	(0.007)	(0.038)

Line items on the amended and restated consolidated statement of cash flows:

	Previously reported	Adjustments	Restated
	\$	\$	\$
Net loss for the year	(5,513,552)	85,937	(5,427,615)
Deferred tax recovery	-	(475,012)	(475,012)
Cash Flows (used in) Operating Activities	(1,413,907)	(389,075)	(1,802,982)
Increase (decrease) in cash	2,499,745	(389,075)	2,110,670
Effect of foreign exchange on cash	(438,556)	389,075	(49,481)

3. Basis of Presentation

(a) Statement of Compliance

The Company's consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). The accounting policies set out below were consistently applied to all periods presented unless otherwise noted.

These consolidated financial statements were reviewed, approved and authorized for issuance by the Board of Directors (the "Board") of the Company on May 28, 2021.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

3. Basis of Presentation (continued)

(b) Basis of Measurement

These consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments carried at fair value, as explained in the accounting policies as set out in Note 4. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

(c) Basis of Consolidation

These consolidated financial statements include the accounts of the Company and its subsidiaries, as follows:

Name	Jurisdiction	Percentage Owned
Pharmadrug Inc.	Ontario, Canada	100%
Aura Health Corp.	Ontario Canada	100%
Interrobang Ltd.	Ontario, Canada	100%
Green Global Properties Inc.	Delaware, U.S.	100%
Pharmadrug Production GmbH	Hamburg, Germany	80%
Interrobang Tiel B.V.	Tiel, Netherlands	100%

Subsidiaries consist of entities over which the Company is exposed to, or has rights to, variable returns as well as the ability to affect those returns through the power to direct the relevant activities of the entity. Subsidiaries are fully consolidated from the date control is transferred to the Company and are de-consolidated from the date control ceases. The consolidated financial statements include all the assets, liabilities, revenues, expenses and cash flows of the Company and its subsidiaries after eliminating inter-entity balances and transactions.

(d) Functional Currency

These consolidated financial statements are presented in Canadian dollars (“\$” or “CAD”), which is the Company’s functional currency. The functional currency is the currency of the primary economic environment in which the Company operates. The functional currency of the subsidiaries is: (i) CAD for Aura Health Corp. and Interrobang Ltd. (“Interrobang”), (ii) U.S. dollar (“USD”) for Green Global Properties Inc. (“Green Global”), and (iii) Euro (“€” or “EUR”) for Pharmadrug GmbH and Interrobang Tiel B.V.

(e) Significant Accounting Judgments and Estimates

The preparation of these consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, revenue, and expenses. On an ongoing basis, management evaluates its judgments and estimates in relation to assets, liabilities, revenue, and expenses. Management uses historical experience and various other factors it believes to be reasonable under the given circumstances as the basis for its judgments and estimates. Actual outcomes may differ from these estimates under different assumptions and conditions. These estimates are reviewed periodically, and adjustments are made as appropriate in the period they become known. Items for which actual results may differ materially from these estimates are described as follows:

Going concern

At each reporting period, management exercises judgment in assessing the Company’s ability to continue as a going concern by reviewing the Company’s performance, resources, and future obligations. The conclusion that the Company will be able to continue as a going concern is subject to critical judgments of management with respect to assumptions surrounding the short and long-term operating budgets, expected profitability, investment and financing activities and management’s strategic planning. The assumptions used in management’s going concern assessment are derived from actual operating results along with industry and market trends, and are consistent with those used to evaluate impairment of goodwill and intangible assets as at December 31, 2020. Management believes there is sufficient capital to meet the Company’s business obligations for at least the next 12 months, after taking into account expected cash flows and the Company’s cash position at year-end.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

3. Basis of Presentation (continued)

(e) Significant Accounting Judgments and Estimates (continued)

Business combination

In a business acquisition, substantially all identifiable assets, liabilities and contingent liabilities acquired are recorded at the acquisition date at their respective fair values. The date on which the acquirer obtains control of the acquiree is generally the date on which the acquirer legally transfers the consideration, acquires the assets and assumes the liabilities of the acquiree – the closing date. However, the acquirer might obtain control on a date that is either earlier or later than the closing date. Management exercises judgment in considering all pertinent facts and circumstances in identifying the acquisition date.

Classification of an acquisition as a business combination or an asset acquisition depends on whether the assets acquired constitute a business, which can be a complex judgment. Whether an acquisition is classified as a business combination or asset acquisition can have a significant impact on the entries made on and after acquisition. In determining the fair value of all identifiable assets, liabilities and contingent liabilities acquired, the most significant estimates relate to contingent consideration and intangible assets.

Management exercises judgment in estimating the probability and timing of when earn-outs are expected to be achieved which is used as the basis for estimating fair value. For any intangible asset identified, depending on the type of intangible asset and the complexity of determining its fair value, an independent valuation expert or management may develop the fair value, using appropriate valuation techniques, which are generally based on a forecast of the total expected future net cash flows. The evaluations are linked closely to the assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied. Purchase consideration also includes consideration of any pre-existing relationships that are effectively settled as a result of the acquisition at their fair values.

Fair value of financial assets and financial liabilities

Fair value of financial assets and financial liabilities on the consolidated statements of financial position that cannot be derived from active markets, are determined using a variety of techniques including the use of valuation models. The inputs to these models are derived from observable market data where possible, but where observable market data are not available, judgment is required to establish fair values. Judgments include, but are not limited to, consideration of model inputs such as volatility, estimated life and discount rates.

Estimated useful lives, depreciation of property and equipment and amortization of intangible assets

Depreciation of property and equipment is dependent upon estimates of useful lives which are determined through the exercise of judgment. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts which take into account factors such as economic conditions, market conditions and the useful lives of assets.

Amortization of intangible assets is dependent upon estimates of useful lives and residual values which are determined through the exercise of judgment. Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions.

Determination of cash generating units

For the purpose of impairment testing, assets that cannot be tested individually are grouped at the lowest levels for which there are largely independent cash inflows. The Company determines which groups of assets (each a “Cash-Generating Unit” or a “CGU”) can generate cash flows that are largely independent of other operations within the Company. Management exercises judgment in assessing where active markets exist including an analysis of the degree of autonomy each operation has in negotiating prices with customers. The Company has identified the German subsidiary as a separate CGU, based on the nature of the business and the assessment that the CGUs generate cash flows that are largely independent of the cash flows from other assets deployed in the Company.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

3. Basis of Presentation (continued)

(e) Significant Accounting Judgments and Estimates (continued)

Impairment

Long-lived assets, including property and equipment and intangible assets, are reviewed for indicators of impairment at each reporting period or whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is defined as the higher of: (i) value-in-use; or (ii) fair value less cost to sell. If the carrying amount of an asset exceeds its recoverable amount, an impairment charge is recognized immediately in profit or loss by the amount by which the carrying amount of the asset exceeds the recoverable amount.

Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the lesser of the revised estimate of recoverable amount, and the carrying amount that would have been recorded had no impairment loss been recognized previously.

Goodwill is tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount of goodwill has been impaired. In order to determine if the value of goodwill has been impaired, the CGU or group of CGUs to which goodwill has been allocated is valued using present value techniques. The Company assesses impairment by comparing the recoverable amount of a long-lived asset, CGU, or CGU group to its carrying value. The determination of the recoverable amount involves significant estimates and assumptions. When applying this valuation technique, the Company relies on a number of factors, including historical results, business plans, forecasts and market data. Changes in the conditions for these judgments and estimates can significantly affect the assessed value of goodwill.

Warrants and options

Warrants and options are initially recognized at fair value, based on the application of the Black-Scholes valuation model (“Black-Scholes”). This pricing model requires management to make various assumptions and estimates which are susceptible to uncertainty, including the expected volatility of the share price, expected forfeitures, expected dividend yield, expected term of the warrants or options, and expected risk-free interest rate.

Income taxes

Income taxes and tax exposures recognized in the consolidated financial statements reflect management’s best estimate of the outcome based on facts known at the reporting date. When the Company anticipates a future income tax payment based on its estimates, it recognizes a liability. The difference between the expected amount and the final tax outcome has an impact on current and deferred taxes when the Company becomes aware of this difference.

In addition, when the Company incurs losses that cannot be associated with current or past profits, it assesses the probability of taxable profits being available in the future based on its budgeted forecasts. These forecasts are adjusted to take account of certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate the sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences.

In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be impacted.

Expected credit losses on financial assets

Determining an allowance for expected credit losses (“ECL”) for amounts receivable and all debt financial assets not held at fair value through profit or loss (“FVTPL”) requires management to make assumptions about the historical patterns for the probability of default, the timing of collection and the amount of incurred credit losses, which are adjusted based on management’s judgment about whether economic conditions and credit terms are such that actual losses may be higher or lower than what the historical patterns suggest.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

3. Basis of Presentation (continued)

(e) Significant Accounting Judgments and Estimates (continued)

Provisions

The Company recognizes provisions if there is a present obligation as a result of a past event, it is probable that the Company will be required to settle the obligation and the obligation can be reliably estimated. The amount recognized as a provision reflects management's best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation.

4. Summary of Significant Accounting Policies

(a) Cash

Cash in the consolidated statements of financial position comprises cash at chartered banks in Canada, Germany and the Netherlands, and funds held in trust with the Company's legal counsel which is available on demand.

(b) Revenue from Contracts with Customers

The Company's policy for the timing and amount of revenue to be recognized is based on the following 5-step process:

- Identify the contract with a customer.
- Identify the performance obligations in the contract.
- Determine the transaction price, which is the total consideration provided by the customer.
- Allocate the transaction price among the performance obligations in the contract based on their relative fair values; and
- Recognize revenue when the relevant criteria are met for each unit (at a point in time or over time).

Revenue is recognized at the transaction price, which is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods to a customer. Net revenue from sale of goods, as presented in the consolidated statements of loss and comprehensive loss, represents revenue from the sale of goods less expected price discounts.

The Company's contracts with customers for the distribution of cannabis and psychedelic products consist of one only performance obligation. The Company has concluded that revenue from the sale of these products should be recognized at the point in time when control is transferred to the customer, which is on shipment or delivery, depending on the contract.

The Company's payment terms vary by customer types. Typically, payment is due 10 days after the transfer of control.

(c) Financial Instruments

Financial assets and financial liabilities, including derivatives, are recognized on the consolidated statements of financial position when the Company becomes a party to the financial instrument or derivative contract.

Classification

The Company classifies its financial assets in the following measurement categories: (a) those to be measured subsequently at FVTPL; (b) those to be measured subsequently at fair value through other comprehensive income ("FVTOCI"); and (c) those to be measured at amortized cost. The classification of financial assets depends on the business model for managing the financial assets and the contractual terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as those to be measured subsequently at FVTPL (irrevocable election at the time of recognition). For assets and liabilities measured at fair value, gains or losses are recorded in profit or loss.

The Company reclassifies financial assets when and only when its business model for managing those assets changes. Financial liabilities are not reclassified.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

4. Summary of Significant Accounting Policies (continued)

(c) Financial Instruments (continued)

Classification (continued)

The Company's financial assets include cash, other receivables excluding any sales tax amounts, note receivable, and other investments. The Company's financial liabilities include its accounts payable and accrued liabilities, loans payable, notes payable, lease liabilities and convertible debentures.

Fair value through profit or loss

This category includes derivative instruments as well as quoted equity instruments which the Company has not irrevocably elected, at initial recognition or transition, to classify at FVTOCI. This category would also include debt instruments whose cash flow characteristics fail the solely principal and interest ("SPPI") criterion or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized in the consolidated statements of loss and comprehensive loss.

Financial assets at fair value through other comprehensive income

Equity instruments that are not held-for-trading can be irrevocably designated to have their change in FVTOCI instead of through profit or loss. This election can be made on individual instruments and is not required to be made for the entire class of instruments. Attributable transaction costs are included in the carrying value of the instruments. Financial assets at FVTOCI are initially measured at fair value and changes therein are recognized in other comprehensive income (loss). As at December 31, 2020, the Company did not have any financial assets at FVTOCI.

Amortized cost

This category includes financial assets that are held within a business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. Financial asset classified in this category are measured at amortized cost using the effective interest method.

The Company's classification of financial assets and financial liabilities is summarized below:

Cash	Amortized cost
Other receivables (excluding sales tax recoverable)	Amortized cost
Note receivable	Amortized cost
Other investments	FVTPL
Accounts payable and accrued liabilities	Amortized cost
Loans payable	Amortized cost
Notes payable	Amortized cost
Lease liabilities	Amortized cost
Convertible debentures	Amortized cost

Measurement

All financial instruments are required to be measured at fair value on initial recognition, plus, in the case of a financial asset or financial liability not at FVTPL, transaction costs that are directly attributable to the acquisition or issuance of the financial asset or financial liability. Transaction costs of financial assets and financial liabilities carried at FVTPL are expensed in profit or loss. Financial assets and financial liabilities with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.

Financial assets that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal outstanding are generally measured at amortized cost at the end of the subsequent accounting periods. All other financial assets including equity investments are measured at their fair values at the end of subsequent accounting periods, with any changes taken through profit and loss or other comprehensive income (loss) (irrevocable election at the time of recognition). For financial liabilities measured subsequently at FVTPL, changes in fair value due to credit risk are recorded in other comprehensive income (loss).

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

4. Summary of Significant Accounting Policies (continued)

(c) Financial Instruments (continued)

Expected credit loss impairment model

Under IFRS 9 – Financial Instruments, the Company recognizes a provision for ECL on financial assets that are measured on amortized cost. The Company assumes that the credit risk on a financial asset has increased significantly if it is more than 30 days past due. The Company considers a financial asset to be in default when the borrower is unlikely to pay its credit obligations to the Company in full or when the financial asset is more than 90 days past due.

The carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts.

Derecognition

The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity.

The Company derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expire. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and/or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value.

Gains or losses on derecognition are generally recognized in profit or loss.

Determination of fair value

The determination of fair value requires judgment and is based on market information, where available and appropriate. The Company classifies fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements.

The fair value hierarchy has the following levels:

- Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 – Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 – Inputs for the asset or liability that are not based on observable market data (unobservable inputs).

(d) Inventories

Inventories are initially recognized at cost, and subsequently measured at the lower of cost and net realizable value (the estimate selling price in the ordinary course of business less estimated costs of completion and estimated costs necessary to make the sale) using the “first-in first-out” method. Cost comprises all costs of purchase, and other costs incurred in bringing the inventories to their present location and condition.

(e) Compound Instruments

The components of compound instruments issued by the Company are classified separately as financial liabilities and equity in accordance with the contractual agreement. At the date of issue, the fair value of the liability component is estimated using the market interest rate then in effect for a similar non-convertible instrument. This amount is recorded as a liability, at amortized cost, using the effective interest rate method until its expiry at the time of conversion or maturity of the instrument. The equity component is determined by deducting the amount of the liability component of the total fair value of the compound instrument. This amount is recognized in equity, net of income tax effects, and is not subsequently remeasured.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

4. Summary of Significant Accounting Policies (continued)

(e) Compound Instruments (continued)

Transaction costs related to the issuance of the convertible debentures are allocated to the liability and equity components in proportion to their initial carrying amounts. Transaction costs relating to the liability component are included in the carrying amount of the liability component and are amortized over the life of the convertible debentures using the effective interest method. Interest and accretion expense are recognized as a finance cost in the consolidated statements of loss and comprehensive loss.

In situations where the convertible debentures contain contractual terms that result in the potential adjustment in the conversion or exercise price, the conversion feature does not meet equity classification and is accounted for as a derivative liability as the fair value is affected by changes in the fair value of the Company's common shares. The effect is that the debt component will be accounted for at amortized cost, with the derivative liability being measured at fair value with changes in value being recorded in profit or loss.

(f) Intangible Assets

Intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. The estimated useful life, amortization method, and residual values are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Amortization is provided over the estimated useful lives as follows:

Supply relationship	Straight-line basis over 5 years
Licenses and permits	Straight-line basis over 5 years

Goodwill

Goodwill represents the excess of the purchase price paid for the acquisition of a business over the fair value of the net tangible and intangible assets acquired. Goodwill is allocated to the CGU or CGUs which are expected to benefit from the synergies of the combination. Goodwill has an indefinite useful life that is not subject to amortization and is tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Impairment on goodwill is determined by assessing if the carrying value of a CGU, including the allocated goodwill, exceeds its recoverable amount determined as the greater of the estimated fair value less costs to sell and the value in use. Impairment losses recognized in respect of a CGU are first allocated to the carrying value of goodwill and any excess is allocated to the carrying amount of assets in the CGU. Any impairment loss for goodwill is recognized directly in profit or loss and any impairment loss recognized for goodwill is not reversed in subsequent periods.

(g) Property and Equipment

Property and equipment are carried at cost less accumulated depreciation and impairment losses. Cost includes the acquisition costs or construction costs, as well as the costs directly attributable to bringing the asset to the location and condition necessary for its use in operations. When property and equipment include significant components with different useful lives, they are recorded and amortized separately.

Depreciation is computed using the straight-line method based on the estimated useful life of the assets and commences when title and ownership have transferred to the Company and is readily available for its intended use. The residual value, useful life and depreciation methods are reviewed at the end of each reporting period. Such a review takes into consideration the nature of the asset, the intended use and impact of technological changes. Where parts of an item of property and equipment have different useful lives, they are accounted for as separate items of capital assets. Subsequent costs are included in the asset carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

4. Summary of Significant Accounting Policies (continued)

(g) Property and Equipment (continued)

Depreciation is recorded on a straight-line basis as follows:

- Office equipment: Straight-line over the term of the lease
- Right-of-use (“ROU”) assets: Straight-line over the term of the lease

(h) Leased Assets

The Company primarily leases office facilities, warehouses, equipment and vehicles. The Company assesses service arrangements to determine if an asset is explicitly or implicitly specified in the agreement and if we have the right to control the use of the identified asset.

At inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company then recognizes a ROU asset and a lease liability at the lease commencement date. The ROU asset is initially measured based on the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The assets are depreciated to the earlier of the end of the useful life of the ROU asset or the lease term using the straight-line method. The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. The Company elected to recognize expenses for leases with a term of 12 months or less on a straight-line basis over the lease term and lease of assets of low value, and not to recognize these short-term leases on the consolidated statements of financial position.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the Company’s incremental borrowing rate which was determined to be between 1.5% to 2% in Germany. The lease liability is measured at amortized cost using the effective interest method. It is remeasured when there is a change in the Company’s estimate of the amount expected to be payable under a residual value guarantee, if there is a change in future lease payments arising from a change in an index or rate, or if the Company changes its assessment whether it will exercise a purchase, extension or termination option.

When the lease liability is remeasured, the amount of the remeasurement is recognized as a corresponding adjustment to the carrying amount of the ROU asset, or is recorded in profit or loss if the carrying amount of the ROU asset has been reduced to zero.

(i) Provisions

A provision is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and the amount of the obligation can be reliably estimated. If the effect is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability.

A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract.

(j) Income Taxes

Income tax expense consists of current and deferred tax expense. Current and deferred tax are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or other comprehensive income.

Current income tax is recognized and measured at the amount expected to be recovered from, or payable to, the taxation authorities based on the income tax rates enacted or substantively enacted at the end of the reporting period and includes any adjustment to taxes payable in respect of previous years.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

4. Summary of Significant Accounting Policies (continued)

(j) Income Taxes (continued)

Deferred tax is recorded for temporary differences at the date of the consolidated statements of financial position between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of a deferred tax asset is reviewed at the end of the reporting period and is reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at the end of the reporting period and are recognized to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the end of the reporting period.

Deferred tax assets and deferred tax liabilities are offset if, and only if, they relate to income taxes levied by the same taxation authority and the Company has the legal rights and intent to offset.

Estimates

Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the final outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made.

(k) Share Capital

In situations where the Company issues units, the value of units is bifurcated and the value of warrants is included as a separate reserve for warrants of the Company's equity. The proceeds from the issuance of units are allocated between common shares and warrants on a pro-rated basis using the relative fair value method. The fair value of the common shares is determined using the share price at the date of issuance of the units. The fair value of the warrants is determined using Black-Scholes.

(l) Share Issuance Costs

Costs incurred in connection with the issuance of share capital are netted against the proceeds received. Costs related to the issuance of share capital and incurred prior to issuance are recorded as deferred share issuance costs and subsequently netted against proceeds when they are received.

(m) Share-Based Payments Transactions

The Company operates an employee stock option plan. Share-based payments to employees are measured at the fair value of the instruments issued and amortized over the vesting periods. Share-based payments to non-employees are measured at the fair value of goods or services received, or at the fair value of the equity instruments issued, if it is determined the fair value of the goods or services cannot be reliably measured and are recorded at the date the goods or services are received. The fair value of options is determined using Black-Scholes. The fair value of equity-settled share-based compensation transactions are recognized as an expense with a corresponding increase in the reserve for share-based payments.

Amounts recorded for cancelled or expired unexercised options are transferred to retained earnings (deficit) in the period of which the cancellation or expiry occurs. Expired warrants are also transferred to retained earnings (deficit).

Upon the exercise of stock options and warrants, proceeds received from the stock option or warrant holders are recorded as an increase to share capital and the related reserves is transferred to share capital.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

4. Summary of Significant Accounting Policies (continued)

(n) Loss Per Share

Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per share is calculated by the treasury stock method. Under the treasury stock method, the weighted average number of common shares outstanding for the calculation of diluted (loss) earnings per share assumes that the proceeds to be received on the exercise of dilutive share options and warrants are used to repurchase common shares at the average market price during the period.

(o) Foreign Currency Translation

Monetary assets and liabilities denominated in currencies other than CAD are translated into CAD at the rate of exchange in effect at the consolidated statements of financial position date. Non-monetary assets and liabilities are translated at the historical rates. Revenues and expenses are translated at the transaction exchange rate. Foreign currency gains or losses resulting from translation are reflected in net comprehensive loss for the period.

The assets and liabilities of entities with a functional currency that differs from the presentation currency are translated to the presentation currency as follows:

- Assets and liabilities are translated at the closing rate at the financial period;
- Income and expenses are translated at average exchange rates (unless the average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case, income and expenses are translated at the rate on the dates of the transactions);
- Equity transactions are translated using the exchange rate at the date of the transaction; and
- All resulting exchange differences are recognized as a separate component of equity as reserve for foreign exchange.

When a foreign operation is disposed of, the relevant amount in the reserve for foreign exchange in other comprehensive income (loss) is transferred to profit or loss as part of the profit or loss on disposal.

On the partial disposal of a subsidiary that includes a foreign operation, the relevant proportion of such cumulative amount is reattributed to non-controlling interest. In any other partial disposal of a foreign operation, the relevant proportion is reclassified to profit or loss.

Foreign exchange gains or losses arising from a monetary item receivable from or payable to a foreign operation, the settlement of which is neither planned nor likely to occur in the foreseeable future, and which in substance, is considered to form part of the net investment in the foreign operation, are recognized in the reserve for foreign exchange.

(p) Related Party Transactions

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence. Related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

4. Summary of Significant Accounting Policies (continued)

(q) Adoption of New Accounting Standards

The Company adopted the following amendments, effective January 1, 2020. These changes were made in accordance with the applicable transitional provisions:

IAS 1 – Presentation of Financial Statements (“IAS 1”) and IAS 8 – Accounting Policies, Changes in Accounting Estimates and Errors (“IAS 8”)

IAS 1 and IAS 8 were amended in October 2018 to refine the definition of materiality and clarify its characteristics. The revised definition focuses on the idea that information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements. The Company had assessed that the adoption of these amendments did not have any material impact on the consolidated financial statements.

Conceptual Framework

On March 29, 2018, the IASB issued its revised Conceptual Framework for financial reporting. The revised Conceptual Framework does not constitute a substantial revision from the previously effective guidance, but does provide additional guidance on topics not previously covered such as presentation and disclosure. This revision was effective on January 1, 2020. The Company had assessed that the adoption of the revised Conceptual Framework did not have any material impact on the consolidated financial statements.

(r) Recent Accounting Pronouncements

As at the date of authorization of these consolidated financial statements, the IASB and the IFRS Interpretations Committee had issued certain pronouncements that are mandatory for the Company’s accounting periods commencing on or after January 1, 2021. Many are not applicable or do not have a significant impact to the Company, have been excluded. The Company had assessed that no material impact is expected upon the adoption of the following amendments on its consolidated financial statements:

Amendments to IAS 1

In January 2020, the IASB issued amendments to IAS 1 which clarify the requirements for classifying liabilities as either current or non-current by: (i) specifying that the conditions which exist at the end of the reporting period determine if a right to defer settlement of a liability exists; (ii) clarifying that settlement of a liability refers to the transfer to the counterparty of cash, equity instruments, other assets or services; (iii) clarifying that classification is unaffected by management’s expectation about events after the balance sheet date; and (iv) clarifying the classification requirements for debt an entity may settle by converting it into equity.

The amendments clarify existing requirements, rather than make changes to the requirements, and so are not expected to have a significant impact on an entity’s financial statements. However, the clarifications may result in reclassification of some liabilities from current to non-current or vice-versa, which could impact an entity’s loan covenants. Because of this impact, the IASB has provided a longer effective date to allow entities to prepare for these amendments. In July 2020, the IASB issued an amendment to defer the effective date of the amendments by one year from its originally planned effective date to annual periods beginning on or after January 1, 2023 due to the impact of COVID-19. Early application is permitted.

Amendments to IAS 37 – Provisions, Contingent Liabilities and Contingent Assets (“IAS 37”)

In May 2020, the IASB issued amendments to update IAS 37. The amendments specify that in assessing whether a contract is onerous under IAS 37, the cost of fulfilling a contract includes both the incremental costs and an allocation of costs that relate directly to contract activities. The amendments also include examples of costs that do, and do not, relate directly to a contract. These amendments are effective for annual periods beginning on or after January 1, 2022. Earlier application is permitted.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

5. Business Acquisitions

Pharmadrug Acquisition

On February 27, 2019, the Company entered into a definitive share purchase agreement (the “Share Purchase Agreement”) to acquire an 80% ownership in Pharmadrug GmbH (the “Pharmadrug Acquisition”), for a purchase price of €4.6 million settled in cash (\$7,101,848). The seller, Anquor Pharmaceuticals Ug (“Anquor”), retains a 20% interest in Pharmadrug GmbH.

In addition, the Company had advanced €400,000 (approximately \$601,520) to Pharmadrug GmbH as a shareholder loan to assist the German subsidiary to maintain appropriate levels of working capital. The Share Purchase Agreement provides that Anquor will be entitled to receive an earn-out payment of €400,000 if the total revenues of the pharmaceutical tender business of Pharmadrug GmbH for the 2019 financial year are 90% or more of the total revenues of that business segment for the 2018 financial year. The earn-out, if any, will be due and payable to Anquor on March 1, 2020. As at December 31, 2019, the earn-out had not been achieved. Thus, no pay-out has been made.

On May 17, 2019 (the “Acquisition Date”), the Company completed the Pharmadrug Acquisition. Goodwill of \$4,605,861, which is not tax deductible, was recognized due to the expected synergies from combining operations of the Company and Pharmadrug GmbH. The Company determined that the Pharmadrug Acquisition was a business combination in accordance to the definition of IFRS 3 – Business Combination (“IFRS 3”), and as such, had accounted for it in accordance with this standard, with the Company being the acquirer on the Acquisition Date.

The following table sets forth the allocation of the purchase price to the net identifiable assets acquired, based on estimates of fair value:

	\$
Purchase Price Consideration Paid	
Cash	7,101,848
Non-Controlling Interest	
Non-Controlling interest	1,729,370
Net Identifiable Assets Acquired	
Cash	618,498
Other receivables	1,161,325
Inventories	15,327
Prepaid expenses and other assets	25,979
Property and equipment, including right-of-use assets	135,245
Intangible assets	
Supply relationship	406,026
Licenses and permits	5,714,440
Accounts payable and accrued liabilities	(120,296)
Lease liabilities	(118,140)
Income tax payable	(228,811)
Other liabilities	(1,468,556)
Provisions	(1,504)
Deferred tax liabilities	(1,914,176)
Total Net Identifiable Assets Acquired	4,225,357
Goodwill	4,605,861

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

5. Business Acquisitions (continued)

Super Smart Transaction

On May 25, 2020 and as amended on June 12, 2020, the Company entered into a definitive agreement (the “Amalgamation Agreement”) with Interrobang d/b/a Super Smart, pursuant to which Pharmadrug acquired all of the issued and outstanding shares of Super Smart, to be effected by way of a three-cornered amalgamation between Pharmadrug, Super Smart and a wholly-owned subsidiary of Pharmadrug (the “Super Smart Transaction”).

On June 15, 2020 (the “Super Smart Transaction Date”), the Super Smart Transaction closed. Pursuant to the terms of the Super Smart Transaction, each Super Smart share, warrant or finder’s warrants was exchanged for one equivalent security in the capital of Pharmadrug. Super Smart previously issued on May 23, 2020, 2,500 subscription receipts (the “Debentures Subscription Receipts”) for an outstanding principal amount of \$2,500,000 of senior secured convertible debentures (the “Super Smart Debentures”). Each Debentures Subscription Receipt entitles the holder to receive, without payment of any additional consideration or further action, and subject to adjustment, one 12% senior secured Super Smart Debenture automatically immediately prior to the completion of the Super Smart Transaction. The purchase price and other terms of the Super Smart Transaction were negotiated at arm’s length with the Board of Pharmadrug and Interrobang.

Following completion of the Super Smart Transaction, Interrobang became a wholly-owned subsidiary of Pharmadrug.

The acquisition of Super Smart does not constitute a business combination because this entity did not meet the definition of a business under IFRS 3. As a result, the transaction has been accounted for in accordance with IFRS 2 – Share-Based Payments (“IFRS 2”), and share consideration paid was measured at the fair value of the identifiable and unidentifiable assets acquired. Consideration consisted entirely of shares and warrants of the Company which were measured at the estimated fair value on the date of the acquisition.

Details of the Super Smart Transaction are presented as follows:

	\$
Purchase Price Consideration Paid	
Fair value of common shares issued ⁽ⁱ⁾	2,886,000
Fair value of warrants issued ⁽ⁱⁱ⁾	1,749,765
	4,635,765
Net Identifiable Assets Acquired	
Cash	2,191,932
Advances	400,000
Promissory note	76,975
Accounts payable and accrued liabilities	(27,667)
Other liabilities	(1,000)
Debentures Subscription Receipts	(2,500,000)
Total Net Identifiable Assets Acquired	140,240
Unidentifiable Assets Acquired	4,495,525

The unidentifiable assets acquired consist largely of the synergies and economies of scale expecting from combining the operations of the Company and Interrobang. The synergies include improved sales and marketing, lower management salaries and wages, and potential supply chain efficiencies in combining the cannabis distribution and psychedelic business.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

5. Business Acquisitions (continued)

Super Smart Transaction (continued)

Consideration paid consisted entirely of shares and warrants of the Company which were measured at the estimated fair value on the date of the Super Smart Transaction, as follows:

- (i) The fair value of the 44,400,000 common shares, issued to former Super Smart shareholders, was determined to be \$2,886,000 based on the closing share price of Pharmadrug on the Super Smart Transaction Date on June 15, 2020.
- (ii) The estimated fair value of the 32,200,000 warrants as consideration are based on Black-Scholes with the following assumptions: current stock price – \$0.065 per share, expected dividend yield – 0%, expected volatility – 121%, risk-free interest rate – 0.27%, exercise price of \$0.05, and an expected life of three years. In making the assumptions for expected volatility, the Company used the estimated average volatility of comparable companies operating in the cannabis industry.
- (iii) The estimated fair value of the 3,748,400 finders' options as consideration are based on the Monte Carlo option model with the following assumptions: current stock price – \$0.065 per share, expected volatility 97%, risk-free interest rate – 0.29%, and an expected life of two years. In making the assumptions for expected volatility, the Company used the estimated average volatility of comparable companies operating in the cannabis industry.

Smart Shop Acquisition

On August 10, 2020, the Company, through its subsidiary Interrobang Tiel B.V., entered into a purchase and sale agreement with Souveniart JE, pursuant to which Pharmadrug acquired the assets of the seller (the "Smart Shop Acquisition"). On October 1, 2020, the Smart Shop Acquisition closed.

The acquisition of Souveniart JE does not constitute a business combination because this entity did not meet the definition of a business under IFRS 3. As a result, the Company has accounted for the Smart Shop Acquisition as an asset acquisition. Consideration consisted of a cash payment of €10,000 (\$15,805).

Details of the Smart Shop Acquisition are presented as follows:

	\$
Purchase Price Consideration Paid	
Cash	15,805
	15,805
Net Identifiable Assets Acquired	
Inventories	1,561
Total Net Identifiable Assets Acquired	1,561
Unidentifiable Net Assets Acquired	14,243

The unidentifiable net assets acquired consist largely of the synergies and economies of scale expecting from the Smart Shop Acquisition. The synergies include improved sales and marketing, complementary products, and potential complementary geographies and customers.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

6. Other Receivables

	December 31, 2020	December 31, 2019
	\$	\$
Sales taxes receivable	116,978	19,425
Trade receivables	37,342	19,066
Other receivables	29,374	7,532
	183,694	46,023

7. Inventories

As at December 31, 2020, the Company's inventories consisted of finished goods held with Pharmadrug GmbH in Germany, and the Smart Shop in the Netherlands. For the year ended December 31, 2020, inventories of \$501,634 (2019 – \$357,321) were expensed and included in cost of goods sold.

8. Prepaid Expenses

	December 31, 2020	December 31, 2019
	\$	\$
Prepaid insurance	28,187	46,315
Advances made to suppliers and deposits	29,617	24,756
	57,804	71,071

9. Note Receivable

On April 30, 2019, the Company, through Green Global, entered into a definitive purchase and sale agreement (the "Purchase Sale Agreement") with Empower Healthcare Assets Inc. ("Empower"), a wholly-owned subsidiary of Empower Clinics Inc., pursuant to which Empower acquired Pharmadrug's 30% interest in the Sun Valley Clinics (the "Clinics"). As consideration, Green Global received a promissory note issued by Empower in the principal amount of USD \$125,000 (the "Promissory Note"). The Promissory Note bears interest at a rate of 4% per annum, matures on July 31, 2019 and may be prepaid at any time, in whole or in part, without penalty or premium.

On July 30, 2019, payments terms of the Promissory Note were amended as per agreed between the Company and Empower, as follows:

- Additional USD \$15,000 to be paid by Empower, beyond the original USD \$125,000 and its interest, if the principal amount is paid after July 31, 2019, but before August 15, 2019.
- Additional USD \$30,000 to be paid by Empower, beyond the original USD \$125,000 and its interest, if the principal amount is paid after August 15, 2019, but before August 31, 2019.

Including the additional payment of USD \$30,000, as the Promissory Note were unpaid as at August 31, 2019, the Company had recognized a total gain of \$46,616 (USD \$35,131) upon disposition of its interests in the Clinics during the year ended December 31, 2019.

On November 7, 2019, the Company received a partial repayment of \$15,313 (USD \$12,041) from Empower, comprised of payment for the principal amount of \$12,717 (USD \$10,000) and interest of \$2,596 (USD \$2,041). As at December 31, 2019, an amount comprised of the principal amount of \$188,326 (USD \$145,000) and accrued interest of \$2,021 (USD \$1,556) remains outstanding to the Company. Although the Company expected to be paid, as the Promissory Note was more than 30 days past due maturity, an allowance for ECL of \$153,920 was recorded by the Company on the Promissory Note during the year ended December 31, 2019.

On July 16, 2020, Empower settled the overdue balance of \$205,032 under the Promissory Note through the issuance of units. In conjunction to its private placement offering which closed on July 14, 2020, Empower issued 4,100,634 units ("Empower Units") at a price of \$0.05 per Empower Unit to the Company.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

9. Note Receivable (continued)

Each Empower Unit is comprised of one common share in the capital of Empower (“Empower Shares”), and one common share purchase warrant (“Empower Warrants”) exercisable at \$0.12 per Empower Warrant, expiring on July 14, 2022. The Empower Shares and Warrants are carried at FVTPL with the estimated fair value of the Empower Warrants based on Black-Scholes with the following assumptions: current stock price – \$0.06 per share, expected dividend yield – 0%, expected volatility – 180%, risk-free interest rate – 0.27%, exercise price of \$0.05, and an expected life of three years. In making the assumptions for expected volatility, the Company used the estimated volatility using Empower’s historical share prices. As a result of the settlement, the Company recorded a reversal of ECL of \$155,614 on the Promissory Note, and a gain on settlement of \$156,331 on its consolidated statements of loss and comprehensive loss during the year ended December 31, 2020.

10. Other Investments

FSD Pharma Inc.

On April 17, 2019, Pharmadrug entered into a share exchange transaction (the “Share Exchange Agreement”) with FSD Pharma Inc. (“FSD”), a licensed producer under the Cannabis Act (Canada), whereby, among other things, FSD issued 13,181,019 FSD Class B Subordinate Voting Shares (the “FSD Shares”) valued at \$3 million to the Company in exchange (the “FSD Share Exchange”) for 13,562,387 Pharmadrug common shares (“Pharmadrug Shares”) valued at \$3 million. The FSD Shares were collateralized by the Company against a Bridge Loan Facility (defined hereafter in Note 14) received from a private lender (the “Lender”).

The Company classifies the FSD Shares at FVTPL, with gains and losses recorded in the consolidated statements of loss and comprehensive loss.

The Share Exchange Agreement governing the FSD Share Exchange contains adjustment provisions that depend on the price of the FSD Shares at the end of the statutory hold period. If the volume weighted average trading price of the FSD Shares is lower than the issuance price as of the hold period expiry date, FSD will issue the Company an additional number of FSD shares.

On August 19, 2019, the statutory hold period on the FSD Shares under the Share Exchange Agreement ended, and the FSD Shares were sold for \$1,374,715, which was applied as a partial repayment on the Bridge Loan Facility. A realized loss of \$1,625,285 was recorded on the disposition of the FSD Shares.

On September 19, 2019, FSD issued an additional 12,440,298 common shares of FSD (the “FSD Additional Shares”) to the Company as part of the make-whole provision, subject to the applicable statutory hold period. As the FSD Additional Shares were under the make-whole provision, they were assigned a cost of \$nil. Upon the expiry of the statutory hold period on the FSD Additional Shares, the Company may sell the FSD Additional Shares for gross proceeds that would be further used to repay the outstanding balance of the Bridge Loan Facility.

On October 11, 2019, FSD completed a consolidation of its Class A Multiple Voting Shares and the FSD Shares, each on a 1 to 201 basis (the “Consolidation”). As at December 31, 2019, the Company held a position of 61,892 post-Consolidation FSD Additional Shares measured at a fair value of \$440,052. For the year ended December 31, 2019, the Company had recorded a fair value increase of 440,052 on the FSD Additional Shares.

On January 13, 2020, the remaining 61,892 post-Consolidation FSD Additional Shares were sold for proceeds of \$741,375 which were applied as a partial repayment on the Bridge Loan Facility. During the year ended December 31, 2020, the Company recorded a realized gain of \$221,321 (2019 – a realized loss of \$1,625,285), and a fair value increase of \$80,062 upon the disposition of the FSD Additional Shares.

Empower

Upon receipt of the Empower Units on settlement of the Promissory Note as per disclosed in Note 9, the Empower Shares and Warrants were valued at \$205,032 and were classified at FVTPL. The Company subsequently disposed of its entire position of Empower Shares, including an additional 4,100,634 Empower Shares issued as a result of the exercise of the Empower Warrants for \$492,076, for total proceeds of \$1,373,957. During the year ended December 31, 2020, the Company recorded a realized loss of \$263,932 and a fair value increase of \$784,361 upon the dispositions of the Empower Shares.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

10. Other Investments (continued)

Red Light Holland Corp.

On July 16, 2020, the Company entered into a share exchange agreement (the “RLH Share Exchange”) with Red Light Holland Corp. (“RLH”), an Ontario-based corporation positioned to engage in the production, growth and sale of magic truffles to the legal, recreational market within the Netherlands.

Under the terms of RLH Share Exchange, the Company issued 9,333,333 Units to RLH at a price of \$0.075 per Unit (see Notes 18 and 20 for more details), and RLH issued 4,242,424 units (the “RLH Units”) to Pharmadrug. Each RLH Unit is comprised of one common share in the capital of RLH (a “RLH Share”) and one RLH share purchase warrant (a “RLH Warrant”). Each RLH Warrant entitles the Company to purchase one additional RLH Share at an exercise price of \$0.26 for 48 months from issuance of the RLH Warrant, subject to an accelerated expiry option.

On completion of the RLH Share Exchange, the RLH Shares and RLH Warrants were valued at \$305,836 and \$253,252, respectively, and were classified at FVTPL. As at December 31, 2020, the RLH Shares and Warrants were measured at a total fair value of \$2,269,504. During the year ended December 31, 2020, the Company had recorded a fair value increase of \$1,710,355 on the RLH Shares and RLH Warrants.

11. Property and Equipment

	Right-of-use assets	Office equipment	Total
	\$	\$	\$
Cost at:			
December 31, 2018	-	-	-
Acquired on business acquisition (Note 5)	118,140	23,798	141,938
Additions	-	9,787	9,787
Effects of foreign exchange on translation	(3,574)	(811)	(4,385)
December 31, 2019	114,566	32,774	147,340
Additions	42,043	18,331	60,374
Disposals	(7,796)	-	(7,796)
Effects of foreign exchange on translation	8,053	2,304	10,357
December 31, 2020	156,866	53,409	210,275
Accumulated depreciation at:			
December 31, 2018	-	-	-
Acquired on business acquisition (Note 5)	-	6,692	6,692
Depreciation	26,649	3,457	30,106
Effect of foreign exchange on translation	(246)	(219)	(465)
December 31, 2019	26,403	9,930	36,333
Depreciation	41,500	7,891	49,391
Effect of foreign exchange on translation	1,856	682	2,538
December 31, 2020	69,759	18,503	88,262
Net book value:			
December 31, 2019	88,163	22,844	111,007
December 31, 2020	87,107	34,906	122,013

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

12. Intangible Assets and Goodwill

	Licenses and Permits	Supply Relationship	Goodwill	Total
	\$	\$	\$	\$
Cost at:				
December 31, 2018	-	-	-	-
Acquired on business acquisition (Note 5)	5,723,898	406,026	4,421,492	10,551,416
Effects of foreign exchange on translation	(167,620)	(11,824)	(133,780)	(313,224)
December 31, 2019	5,556,278	394,202	4,287,713	10,238,192
Effects of foreign exchange on translation	390,145	27,214	301,372	718,731
December 31, 2020	5,946,423	421,416	4,589,084	10,956,923
Accumulated depreciation at:				
December 31, 2018	-	-	-	-
Amortization	701,834	49,867	-	751,701
December 31, 2019	701,834	49,867	-	751,701
Amortization	1,162,899	84,283	-	1,247,183
Effect of foreign exchange on translation	73,763	3,460	-	77,222
December 31, 2020	1,938,496	137,610	-	2,076,106
Net book value:				
December 31, 2019	4,854,444	344,335	4,287,713	9,486,491
December 31, 2020	4,007,927	283,806	4,589,084	8,880,817

As at December 31, 2020, the Company reviewed for indicators of impairment for the supply relationship, and the narcotics license for the German operations. Management assessed all available external and internal sources of information, including general market and economic conditions of the German cannabis market, changes to the legal environment, and forecasted cash flows that would be generated by the supply relationship and the narcotics license. Management concluded that there were no events or changes in circumstances which would have indicated that the carrying amount of an asset exceeds its recoverable amount.

As at December 31, 2020, the Company also performed its annual impairment test on goodwill, which compared the carrying amount of Pharmadrug GmbH to the recoverable amount. Pharmadrug GmbH is regarded as its own CGU, being the smallest identifiable group of assets that generates cash inflows, and includes Pharmadrug GmbH's brand name, customer relationships, and goodwill.

Using a five-year discounted cash flow ("DCF") model, the Company determined the recoverable amount by calculating its value-in-use. As of December 31, 2020, management determined that the recoverable amount exceeded the carrying value of Pharmadrug GmbH. Therefore, no impairment was recognized on goodwill on the consolidated statements of loss income and comprehensive loss.

The DCF model in fiscal 2020 included projections surrounding revenue, cost of sales, expenses, discount rate, growth rates, capital expenditures and working capital. The model used an average annual revenue growth rate of 5% from its basic supply, a projected average annualized revenue growth of 158% from a supply agreement entered with new suppliers of cannabis products, increased cost of 60% of total revenue from imports of products, variable costs of 5% of total revenue, average gross margin of 35% and post-tax discount rates of 32%. Operating expenses were projected to grow in line with revenue growth.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

13. Accounts Payable and Accrued Liabilities

	December 31, 2020	December 31, 2019
	\$	\$
Trade payables	353,246	529,219
Accrued liabilities	208,884	604,230
	562,130	1,133,449

Accounts payable and accrued liabilities of the Company are principally comprised of amounts outstanding for trade purchases incurred in the normal course of business.

14. Loans Payable

Bridge Loan Facility

On May 9, 2019, the Company received a \$3 million bridge facility (the “Bridge Loan Facility”) from the Lender, for which the proceeds were applied on closing of the Pharmadrug Acquisition. The Bridge Loan Facility bears interest at a rate of 18% per annum and matures on September 24, 2019. To secure the Bridge Loan Facility, the Company: (i) entered into a general security agreement (“GSA”) with the Lender, (ii) granted the Lender exclusive control over the FSD Shares, and (iii) granted the Lender a power of attorney or trading authority in respect of the FSD shares.

On August 19, 2019, the FSD Shares were sold for \$1,374,715 and the proceeds were applied as a partial repayment on the principal amount of the Bridge Loan Facility.

On October 3, 2019, the Bridge Loan Facility was amended to extend the maturity for a further six months to March 24, 2020 (the “Extended Maturity Date”). In connection to the Extended Maturity Date, the Company agreed to pay the Lender a restructuring fee of \$180,000 (the “Restructuring Fee”), payable in cash or in shares at the option of the Lender, and to also issue to the Lender additional shares having a value equal to 20% of the net proceeds from the sale of the FSD Additional Shares based on Pharmadrug’s share price.

On January 13, 2020, the remaining 61,892 post-Consolidation FSD Shares were sold for \$741,375 and the proceeds were further applied as a partial repayment on the principal amount of the Bridge Loan Facility.

On July 16, 2020, the Company repaid the full balance of the Bridge Loan Facility (the “Settlement”) through a combination of cash payment and issuance of common shares, comprised of: (i) a cash payment of \$1,481,158 to settle the total outstanding principal balance of \$883,910, accrued interest of \$356,561, the Restructuring Fee, related fees and expenses, and any harmonized sale tax (“HST”) outstanding under the Bridge Loan Facility; and (ii) the issuance of 9,566,014 common shares in the capital of Pharmadrug to satisfy in full other fees negotiated between the Company and the Lender, including:

- 2,965,499 common shares issued for a fee of \$148,275 (the “4-Month Hold Inducement Fee”);
- 385,515 common shares issued for \$19,275 in relation to the HST amount on the 4-Month Hold Inducement Fee;
- 5,500,000 common shares issued in full satisfaction of an advisory fee of \$275,000 (the “Advisory Fee”) in relation to a previously entered advisory agreement; and
- 715,000 common shares issued \$33,750 in relation to the HST amount on the Advisory Fee.

During the year ended December 31, 2020, the Company had recorded a gain of \$31,075 (2019 – \$nil) upon completion of the Settlement with the Lender, on its consolidated statements of loss and comprehensive loss.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

14. Loans Payable (continued)

Private loan

On February 7, 2020, the Company secured a private loan (the “Private Loan”) of \$250,000 from an arm’s length third-party lender, in connection to a non-binding LOI previously entered on December 24, 2019. The Private Loan carries an interest rate of 9% per annum accruing every 90 days, payable on maturity with such interest increasing to 15% per annum from the date of the occurrence of an event of default. The Private Loan is secured by: (i) GSAs from the Company and its material subsidiaries, (ii) a pledge of shares by the Company of its interest in Pharmadrug GmbH, and (iii) guarantees from the Company’s material subsidiaries. The Private Loan is due on the earlier of: (i) the closing of a proposed transaction, and (ii) 180 days following the termination of the non-binding LOI. On May 21, 2020, the parties mutually terminated the LOI.

On June 29, 2020, the Company repaid the Private Loan for \$258,897, including accrued interest of \$8,897.

Advances from Super Smart

On May 25, 2020, the Company issued a non-interest bearing unsecured promissory note to Super Smart for a loan of \$80,000. The unsecured promissory note is due and payable on August 25, 2020.

On June 9, 2020, the Company also received advances of \$400,000 from Super Smart for working capital purposes.

On completion of the Super Smart Transaction (see Note 5), the unsecured promissory note and advances due to Super Smart had been eliminated on consolidation.

15. Notes Payable

On January 28, 2019, the Company issued promissory notes (the “Notes”) in the principal amount of \$600,000, bearing interest at 2% per month and due on March 28, 2019. \$400,000 were advanced by the Chief Executive Officer (“CEO”) and the former Chief Operating Officer (“Former COO”) of the Company, with the remaining balance being advanced from an arm’s length third-party.

On July 17, 2020, the Company completed a restructuring on certain of its outstanding indebtedness (the “Restructuring”), of which (i) the \$400,000 principal amount of the Notes owing to the CEO and the arm’s length third-party, plus accrued interest of \$139,209, were exchanged as part of an aggregate of \$1,005,620 principal amount of 12% convertible debentures (the “Replacement Debentures”) maturing on July 17, 2023 (see Note 17(d) for details), and (ii) the remaining \$200,000 principal amount of the Notes owing to the Former COO, plus accrued interest of \$69,604, were exchanged for 5,392,080 Units at a deemed price of \$0.05 per Unit. Each Unit is comprised of one common share and one-half (1/2) of a Warrant exercisable into one common share at \$0.07 per share at any time on or before July 17, 2023 (see Notes 18 and 20 for details).

The Company assessed that pursuant to the terms and conditions of the debt conversion agreements entered between the parties and the Company, all above-mentioned parties had agreed and accepted in full the terms of the Restructuring, which provided evidence that the legal release condition in extinguishing a debt.

16. Lease Liabilities

As part of the German operations under Pharmadrug GmbH, the Company is party to the following lease agreements:

- (i) A lease for its office in Rostock, Germany expiring in June 2022.
- (ii) A lease for office equipment expiring in December 2023.
- (iii) A lease for a vehicle expiring in February 2022; and
- (iv) A lease for its warehouse which expired in December 2020, which was not previously recognized due to the short-term nature and low value of the lease.

In the Netherlands, the Company is party to a lease for its retail location in the town of Tiel, in central Netherlands, expiring in September 2022.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

16. Lease Liabilities (continued)

During the year ended December 31, 2020, the movements and carrying amounts of the Company's ROU assets under leases as per disclosed in Note 11, are summarized as follows:

	Buildings and leaseholds	Office equipment	Total
	\$	\$	\$
Cost at:			
December 31, 2018	-	-	-
Acquired on business acquisition (Note 5)	84,058	34,082	118,140
Effects of foreign exchange on translation	(2,543)	(1,031)	(3,574)
December 31, 2019	81,515	33,051	114,566
Additions	26,584	15,460	42,044
De-recognition	(7,796)	-	(7,796)
Effects of foreign exchange on translation	5,729	2,323	8,052
December 31, 2020	106,032	50,834	156,866
Accumulated depreciation at:			
December 31, 2018	-	-	-
Depreciation	18,961	7,688	26,649
Effect of foreign exchange on translation	(175)	(71)	(246)
December 31, 2019	18,786	7,617	26,403
Depreciation	33,373	15,923	49,296
De-recognition	(7,796)	-	(7,796)
Effect of foreign exchange on translation	1,320	536	1,856
December 31, 2020	45,683	24,076	69,759
Net book value:			
December 31, 2019	62,729	25,434	88,163
December 31, 2020	60,349	26,578	87,107

The following table reflects the reconciliation of the lease liabilities as at December 31, 2020:

	\$
Lease liabilities, January 1, 2019	-
Acquired on business acquisition	118,140
Lease payments	(20,298)
Interest on lease obligations	1,042
Effects of foreign exchange	(4,441)
Lease liabilities, December 31, 2019	94,443
Additions	42,043
Lease payments	(52,349)
Interest on lease obligations	1,967
Effects of foreign exchange	6,650
Lease liabilities, December 31, 2020	92,754
Current	57,173
Non-current	35,581
	92,754

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

16. Lease Liabilities (continued)

The lease liabilities are secured by the related underlying assets. Future minimum lease payments as at December 31, 2020 are as follows:

	Total	Within 1 year	1 to 2 years	2 to 3 years	3 to 4 years
	\$	\$	\$	\$	\$
Lease payments	94,060	58,249	32,351	3,460	-
	94,060	58,249	32,351	3,460	-

17. Convertible Debentures

(a) Series B Debentures

On December 22, 2017, the Company closed a non-brokered private placement of secured convertible debentures (the “Series B Debentures”) for total proceeds of \$600,000. The Series B Debentures bear interest at a rate of 12% per annum and mature on December 22, 2019. The Series B Debentures are convertible at the option of the holder at any time prior to the maturity date into common shares of the Company at a conversion price which shall be the lower of (i) \$0.60 per share, (ii) the price equal to 75% of the Concurrent Financing price, (iii) the lowest price that Pharmadrug common shares are issued from treasury during the period from the Series B Debentures issuance date up to the conversion date, or (iv) if a liquidity event (being the reverse takeover transaction which occurred for the Company on August 9, 2018) has not occurred by June 30, 2018, or such later date agreed by the Series B Debentures holders in writing, the price equal to the higher of (a) \$0.20, and (b) 50% of the lowest price that Pharmadrug shares are issued from treasury during the period from the first liquidity deadline to the conversion date. The Series B Debentures rank pari passu with respect to the security and collateral granted in connection therewith and have first priority security against the Company.

The conversion feature of the Series B Debentures meets the definition of a derivative liability instrument because the conversion rate is variable and therefore does not meet the “fixed-for-fixed” criteria outlined under IFRS. As a result, the conversion feature is required to be recorded as a derivative liability recorded at fair value and marked-to-market each period with the changes in fair value each period being charged or credited to income.

On January 15, 2019, \$300,000 of the Series B Debentures were converted into 2,000,000 common shares of the Company at a conversion price of \$0.15. The debentures and the derivative liability balances of \$315,854 and \$175,600, respectively, were derecognized as a result.

On April 29, 2019, the remaining \$300,000 of the Series B Debentures were converted into 2,000,000 common shares of the Company at a conversion price of \$0.15. The remaining debentures and the derivative liability balances of \$246,065 and \$160,000, respectively, were derecognized as a result. For the period from January 1, 2019 to the conversion date, a loss of \$166,243 was included in fair value change in derivative liability.

(b) Unsecured Debentures

On October 26, 2018, the Company closed a non-brokered private placement offering of unsecured convertible debentures (the “Unsecured Debentures”) for gross proceeds of \$400,000. The Unsecured Debentures bear interest at a rate of 10% per annum, payable quarterly in arrears, and are due on October 26, 2020. Each Unsecured Debenture is convertible at the conversion price of \$0.365 into units of the Company consisting of one common share and one-half (1/2) of a Warrant, with each whole such Warrant exercisable at the conversion price of \$0.50 to acquire one common share of the Company for a period of 24 months from the date of issuance.

Total costs of raising the Unsecured Debentures include legal costs of \$20,000, which had been capitalized.

The Unsecured Debentures are classified as a liability, with the exception of the portion relating to the conversion feature, resulting in the carrying value of the debentures being less than face value. The discount is being accreted over the term of the debentures utilizing the effective interest rate method at a 23.15% discount rate.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

17. Convertible Debentures (continued)

(b) Unsecured Debentures (continued)

On July 17, 2020, the Company completed the Restructuring, of which a \$400,000 principal amount of the Unsecured Debentures, plus accrued interest of \$45,632, were part of the exchange for an aggregate of \$1,005,620 principal amount of Replacement Debentures maturing on July 17, 2023 (see Note 17(d) for more details).

(c) Pharmadrug Debentures

On completion of the Super Smart Transaction, the Debentures Subscription Receipts were converted into the Super Smart Debentures, which were then exchanged pursuant to their terms into debentures of Pharmadrug (the "Pharmadrug Debentures") which bear interest at a rate of 12% per annum from the date of issue payable monthly in cash and ranking pari passu with one another. The Pharmadrug Debentures are secured by first ranking security of Super Smart and second ranking security of Pharmadrug. The Pharmadrug Debentures mature three years from the issuance date, on May 19, 2023 (the "Maturity Date").

Pharmadrug has a right to prepay or redeem a part or the entire principal amount of the Pharmadrug Debentures at par plus accrued and unpaid interest at any time by providing written notice of the date (the "Redemption Date") for such redemption to the holder at least a minimum of 30 days and a maximum 60 days' prior to the Redemption Date. Each Pharmadrug Debenture is convertible into units (each, a "Unit") at the option of the holder at any time prior to the close of the third business day prior to the earlier of: (i) the Maturity Date and (ii) the Redemption Date at a price of \$0.05 per Unit with each Unit consisting of one common share of Pharmadrug (the "Pharmadrug Share") and one-half (1/2) of a common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Pharmadrug Share at an exercise price of \$0.05 for a period of 36 months from the date of issuance of the Pharmadrug Debentures. In the event that the Pharmadrug Shares have a closing price on such exchange on which the Pharmadrug Shares may be traded at such time of greater than \$0.15 per share for a period of 10 consecutive trading days, the Company will be able to cause the Pharmadrug Debentures to be converted into Units.

The Pharmadrug Debentures are compound financial instruments. On initial recognition, the residual value method was used to allocate the fair value of the debt and equity components. The fair value of the liability was calculated as \$2,500,000 using a discount rate of 12%. No proceeds were allocated to the conversion option.

From the period from the completion of the Super Smart Transaction to December 31, 2020, holders had converted a combined total of \$2,215,000, principal amount of the Pharmadrug Debentures resulting in the issuance of 44,300,000 Units of the Company. On conversions, the Company reduced the carrying amount of the liability by \$2,215,000.

From the period from the completion of the Super Smart Transaction to December 31, 2020, the Company had recorded accretion expense on the Pharmadrug Debentures of \$62,135 which is included within interest expense.

(d) Replacement Debentures

On July 17, 2020, the Company completed the Restructuring on certain of its outstanding indebtedness. Under the terms of the Restructuring, (i) the \$400,000 principal amount of the Unsecured Debentures plus accrued interest of \$45,632 (see Note 17(b)), and (ii) the \$400,000 principal amount of the Notes owing to the CEO and an arm's length third-party plus accrued interest of \$139,209 (see Note 15), were exchanged for an aggregate of \$1,005,620 principal amount of the Replacement Debentures. The Replacement Debentures bear interest at a rate of 12% per annum, payable annually in arrears, and are due on July 17, 2023. The Replacement Debentures are convertible into Units at a price of \$0.05 per Unit. Each Unit is comprised of one common share and one-half (1/2) of a Warrant exercisable into one common share at \$0.07 per share at any time on or before July 17, 2023.

The Company also assessed whether the exchange of debt amounted to a substantial modification of the terms of the of the existing debts. The 'exchange' of the debts into the Replacement Debentures is intended to defer the overdue repayment of interest and principal to a later time period. However, the obligations remained with the same creditors. The Company assessed whether the 'exchange' amounted to a substantial modification of the terms of the of the existing debts.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

17. Convertible Debentures (continued)

(d) Replacement Debentures (continued)

In determining whether the change of terms is substantially different, the Company determined whether the present value of the new cash flows under the Replacement Debentures is at least 10% different from the present value of remaining balance under the old debts. It was assessed that the difference is greater than 10%, and the Notes and the Unsecured Debentures were derecognized and accounted for as extinguishments, with the Replacement Debentures being recognize separately.

The present value of the Replacement Debentures was valued at \$791,460, with the present value of the old debts determined to be \$1,005,620 (as the Notes were already due on demand, and with the Unsecured Debentures approaching its maturity, their respective carrying amounts were taken as their present value at the time of the exchange).

The Replacement Debentures are compound financial instruments. On initial recognition, the residual value method was used to allocate the fair value of the debt and equity components. The face value of the liability was calculated using a discount rate of 20%.

The difference between the principal amount of the Replacement Debentures and the discounted cash flows is allocated to the conversion feature which was classified within equity, using the residual value method. Accretion of the liability portion and interest payable on the Convertible Debentures are included in finance costs in the consolidated statements of loss and comprehensive loss.

On December 18, 2020, a principal amount of \$134,802 of the Replacement Debentures were converted into 2,696,045 Units of the Company at a conversion price of \$0.05 when the carrying of the liability was \$115,047.

During the year ended December 31, 2020, the Company had recorded accretion expense on the Replacement Debentures of \$71,668 which is included in finance costs on the consolidated statements of loss and comprehensive loss.

During the year ended December 31, 2020, the Company had recorded a loss of \$20,779 on completion of the exchange of debts for the Replacement Debentures, on the consolidated statements of loss and comprehensive loss.

The following table reflects the continuity of convertible debentures as at December 31, 2020:

	\$
Balance, December 31, 2018	960,198
Interest and accretion expense	78,153
Conversion of debentures into common shares	(561,920)
Payment of interest on debentures	(72,000)
Balance, December 31, 2019	404,431
Issuance on business acquisition (Note 5)	2,500,000
Conversion of Pharmadrug debentures into common shares	(2,215,000)
Extinguishment of Unsecured Debentures	(445,632)
Issuance of Replacement Debentures on settlement	791,460
Interest and accretion expense	175,004
Conversion of Replacement Debentures	(115,047)
Payment of interest on debentures	(62,135)
Balance, December 31, 2020	1,033,081

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

18. Share Capital

Authorized share capital

The Company is authorized to issue an unlimited number of common shares without par value.

Common shares issued and outstanding as at December 31, 2020 and 2019 are as follows:

	Number of common shares	Amount
	#	\$
Balance, December 31, 2018	31,072,567	3,899,096
Shares issued by private placement ^(a)	11,493,998	1,480,836
Share issuance costs ^(a)	-	(32,946)
Shares issued on conversion of Series B Debentures ^{(b), (g)}	4,000,000	897,520
Shares issued by subscription receipts offering ^{(c), (d)}	21,545,454	4,077,660
Share issuance costs ^{(c), (d)}	-	(419,479)
Shares issued on share exchange and corporate finance fee ^{(e), (h)}	14,376,130	3,187,161
Shares issued from exercise of options ^(f)	260,000	39,000
Shares issued for service agreements ⁽ⁱ⁾	300,000	37,500
Shares issued from exercise of warrants ⁽ⁱ⁾	254,125	49,417
Balance, December 31, 2019	83,302,274	13,215,765
Shares issued on business acquisition ^(k)	44,400,000	2,886,000
Shares issued on conversion of Pharmadrug Debentures ^(l)	44,300,000	1,634,387
Shares issued on settlement of bridge loan facility ^(m)	9,566,014	430,471
Shares issued on share exchange ⁽ⁿ⁾	9,333,333	336,420
Shares issued on private placements ^(o)	2,666,667	110,494
Shares issued on restructuring ^(p)	14,437,090	521,684
Shares issued as compensation ^(q)	1,800,000	63,000
Shares issued on conversion of Replacement Debentures ^(r)	2,696,045	107,806
Shares issued from exercise of warrants ^(s)	28,525,000	2,476,167
Shares issued from exercise of finders' warrants ^(t)	73,920	8,003
Shares issued from exercise of finders' options ^(u)	531,840	41,595
Balance, December 31, 2020	241,632,183	21,831,792

Share capital transactions for the year ended December 31, 2019

- (a) On January 10, 2019, the Company closed a non-brokered private placement (the "Private Placement") of 11,493,998 Units at a price of \$0.15 per Unit, for gross proceeds of \$1,724,100. Each Unit is comprised of one common share of the Company and one-half (1/2) of a Warrant exercisable at \$0.25 for a period of 24 months from closing. In connection with the Private Placement, the Company issued 122,160 Finder's Warrants and paid cash commissions of \$18,324. Each Finder's Warrant is exercisable into one common share of the Company at a price of \$0.25 for a period of 24 months from closing (see Note 20 for details).
- (b) On January 15, 2019, the Company issued 2,000,000 common shares as a result of the conversion of \$300,000 of principal of the Series B Debentures at the conversion price of \$0.15 (see Note 17(a)).
- (c) On February 27, 2019, the Company closed the first tranche ("Tranche 1") of an offering of 8,726,954 subscription receipts (each a "Subscription Receipt") (the "Offering") at an issue price of \$0.22 (the "Issue Price") per Subscription Receipt, for gross proceeds of \$1,919,930. Upon satisfaction by the Company of certain Escrow Release Conditions each Subscription Receipt entitles the holder to receive, without any further action on the part of the holder or payment of any additional consideration, one unit of the Company consisting of one common share and one-half (1/2) of a Warrant, with each Warrant exercisable at \$0.28 into one common share for a period of 24 months from the date of satisfaction of the Escrow Release Conditions. In connection with Tranche 1 of the Offering, the Company paid \$224,625 in cash commissions and issued 610,888 Finder's Warrants (see Note 20 for details).

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

18. Share Capital (continued)

Share capital transactions for the year ended December 31, 2019 (continued)

- (d) On April 17, 2019, the Company closed the second tranche (“Tranche 2”) of the Offering of 12,818,500 Subscription Receipts, for gross proceeds of \$2,820,070 under the same terms as Tranche 1. Upon satisfaction of certain Escrow Release Conditions, each Subscription Receipt entitles the holder to receive, without any further action on the part of the holder or payment of any additional consideration, one Unit of the Company consisting of one common share and one-half (1/2) of a Warrant, with each Warrant exercisable at \$0.28 into one common share of the Company for a period of 24 months from the date of satisfaction of the Escrow Release Conditions. In connection with Tranche 2, the Company paid \$262,990 in cash commissions and issued 897,295 Finder’s Warrants (see Note 20 for details).
- (e) On April 17, 2019, 13,562,387 common shares valued at \$3 million were issued in pursuant to the Share Exchange Agreement with FSD (see Note 10).
- (f) On April 25, 2019, 260,000 common shares were issued as a result of the exercise of stock options for cash proceeds of \$26,000.
- (g) On April 29, 2019, the Company issued 2,000,000 common shares as a result of the conversion of the remaining \$300,000 of principal of the Series B Debentures at the conversion price of \$0.15 (see Note 17(a)).
- (h) On May 9, 2019, 813,743 common shares were issued as compensation to the Lead Agent of the Share Exchange in the form of a corporate finance and structuring fee. The grant date fair value of the common shares issued was \$187,161 based on the closing share price on the day of issuance, and the amount was recorded as share-based payments on the consolidated statements of loss and comprehensive loss.
- (i) On June 21, 2019, 300,000 common shares were issued as a result of a service agreement. The grant date fair value of the common shares issued was \$37,500 based on the closing share price on the day of issuance, and the amount was recorded as share-based payments on the consolidated statements of loss and comprehensive loss.
- (j) During the year ended December 31, 2019, 254,125 common shares were issued as a result of the exercise of warrants for cash proceeds of \$38,119.

Escrow Release Conditions

On closing of the Offering, subscription proceeds were placed in escrow with Capital Transfer Agency, ULC, the Company’s transfer agent, on behalf of the subscribers of the Subscription Receipts, to be released to the Company upon satisfaction of certain Escrow Release Conditions, which included, among other things, that:

- (i) All conditions prior to the completion of the Pharmadrug Acquisition have been satisfied or waived in accordance with the terms of the Pharmadrug Acquisition Agreement.
- (ii) There have been no material amendments of the terms and conditions of the Pharmadrug Acquisition Agreement which have not been approved by Mackie Research Capital Corporation, the Lead Agent of the Offering (the “Lead Agent”).
- (iii) The Company has received all necessary regulatory and other approvals regarding the Offering and the Pharmadrug Acquisition.
- (iv) The Company has disposed of all its interests in cannabis operations located in the U.S.
- (v) The Lead Agent is satisfied with its due diligence review with respect to the business, assets, financial condition, operating results, affairs and prospects of the Company; and
- (vi) The Company has delivered all required documents as requested by the Lead Agent.

On May 9, 2019, the Company satisfied all Escrow Release Conditions pursuant to the Offering.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

18. Share Capital (continued)

Share capital transactions for the year ended December 31, 2020

- (k) On June 15, 2020, the Company issued 44,400,000 common shares in exchange for common shares of Super Smart on closing of the Super Smart Transaction (see Note 5).
- (l) During the year ended December 31, 2020, a principal amount of \$2,215,000 of the Pharmadrug Debentures were converted into 44,300,000 Units of the Company at a price of \$0.05 per share. Each Unit is comprised of one common share of the Company and one-half (1/2) of a Warrant exercisable at \$0.05 for a period of 36 months from the date of issuance of the Pharmadrug Debentures (see Note 17(c)).
- (m) On July 16, 2020, the Company issued 9,566,014 common shares to satisfy all remaining fees under the Settlement of the Bridge Loan Facility (see Note 14 for details). These common shares were valued at \$430,471 based on the closing share price on the day of issuance.
- (n) On July 16, 2020, the Company issued 9,333,333 Units to RLH in pursuant to the RLH Share Exchange. Each Unit is comprised of: (i) one common share of Pharmadrug, (ii) 0.9 of a Warrant exercisable into one common share of the Company at a price of \$0.13 for 48 months from issuance, and (iii) 0.1 of a Warrant exercisable into one common share at a price of \$0.08 for 48 months from issuance.
- (o) On July 16, 2020, the Company also issued 2,666,667 Units to RLH at a price of \$0.075 per Unit, for subscription proceeds of \$200,000. Each Unit is comprised of one common share and one Warrant exercisable into one common share at a price of \$0.08 for 48 months from issuance.
- (p) On July 17, 2020, the Company issued 14,437,090 Units to settle: (i) the total outstanding balance owing to the Former COO under the Notes comprised on a \$200,000 principal amount and accrued interest of \$69,604, and (ii) other total obligations of \$452,250, including amounts of \$62,150 and \$77,950 owed to the CEO and the former Chairman, respectively. Each Unit is comprised of one common share and one-half (1/2) of a Warrant exercisable into one common share at \$0.07 per share at any time on or before July 17, 2023 and recorded a gain of \$2,652 in connection with this settlement.
- (q) On August 31, 2020, the Company issued 1,300,000 common shares to an entity controlled by the CEO of the Company, and 500,000 common shares to the Former COO, respectively, as compensation as stipulated by their respective consulting agreement with Pharmadrug. These common shares were valued at \$63,000 based on the closing share price on the day of issuance, and the amount was included in share-based payments on the consolidated statements of loss and comprehensive loss.
- (r) On December 18, 2020, the Company issued 2,696,045 Units as a result of the conversion of \$134,802 of principal of the Replacement Debentures at the conversion price of \$0.05 (see Note 17(d)).
- (s) During the year ended December 31, 2020, 28,525,000 common shares were issued as a result of the exercise of Warrants for cash proceeds of \$1,426,250.
- (t) During the year ended December 31, 2020, 73,920 common shares were issued as a result of the exercise of Finders' Warrants for cash proceeds of \$3,696.
- (u) During the year ended December 31, 2020, 531,840 common shares were also issued as a result of the exercise of broker options for cash proceeds of \$26,592.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

19. Reserve for Share-Based Payments

The Company maintains a stock option plan (the “Option Plan”) whereby certain key officers, directors and consultants may be granted stock options for common shares of the Company. The maximum number of common shares that are issuable under the Option Plan is limited to 10% of the number of issued and outstanding common shares. Under the Option Plan, the exercise price of each option may not be less than the closing price of the Company’s shares on the trading day prior to the grant date or the grant date itself, whichever is higher. Vesting of options is determined at the discretion of the Board.

As at December 31, 2020, the Company had 7,813,218 common shares available for issuance under the Option Plan.

The following summarizes the stock option activity for the years ended December 31, 2020 and 2019:

	December 31, 2020		December 31, 2019	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
	#	\$	#	\$
Outstanding, beginning of year	3,120,000	0.20	2,250,000	0.16
Granted	5,500,000	0.11	1,100,000	0.235
Granted	8,500,000	0.05	550,000	0.22
Granted	1,000,000	0.06	-	-
Exercised	-	-	(260,000)	0.10
Expired	(1,020,000)	0.10	(320,000)	0.10
Cancelled	(350,000)	0.31	(200,000)	0.235
Cancelled	(400,000)	0.22	-	-
Outstanding, end of year	16,350,000	0.09	3,120,000	0.20
Exercisable, end of year	10,725,000	0.10	2,782,500	0.20

Option grants for the year ended December 31, 2019

On January 17, 2019, the Company granted 200,000 options to a former director at an exercise price of \$0.235, expiring on January 17, 2021. The options vested immediately on grant. The Company also granted 350,000 options to a consultant under the same terms and expiry, of which 200,000 options vested immediately on grant, while the remaining 150,000 options vested on April 17, 2019. The options were valued using Black-Scholes with the following assumptions: expected volatility of 77%, expected dividend yield of 0%, risk-free interest rate of 1.90% and an expected life of two years. The grant date fair value attributable to these options of \$45,157 was recorded as share-based compensation in connection with the vesting of these options during the year ended December 31, 2019. As of August 14, 2019, the 200,000 options granted to the former director were cancelled, and the grant date fair value of \$16,421 attributable to these options were reallocated to accumulated deficit.

On May 24, 2019, the Company granted 500,000 options to various consultants at an exercise price of \$0.22, expiring on May 24, 2021. 125,000 options vested immediately on grant, with 125,000 options to be vested on a quarterly basis thereafter. The options were valued using Black-Scholes with the following assumptions: expected volatility of 77%, expected dividend yield of 0%, risk-free interest rate of 1.56% and an expected life of two years. The grant date fair value attributable to these options of \$20,519 of which \$19,467 was recorded as share-based compensation in connection with the vesting of these options during the year ended December 31, 2019.

On May 28, 2019, the Company granted 600,000 options to a consultant at an exercise price of \$0.22, expiring on May 28, 2021. Of the 600,000 options granted, 475,000 options vested immediately on grant, with the remaining 125,000 options to be vested depending on certain performance conditions as follows:

- 62,500 options to be vested after the first cannabis plant is potted at a greenhouse facility in Netanya (the “Facility”) from a past investment in Israel; and
- 62,500 options to be vested after the first commercial harvest at the Facility.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

19. Reserve for Share-Based Payments (continued)

Option grants for the year ended December 31, 2019 (continued)

The options were valued using Black-Scholes with the following assumptions: expected volatility of 77%, expected dividend yield of 0%, risk-free interest rate of 1.53% and an expected life of two years. The grant date fair value attributable to 475,000 options of \$22,209 was recorded as stock-based compensation in connection with the vesting of these options during the year ended December 31, 2019.

In accordance with IFRS 2, the fair value treatment of performance-based vesting conditions is dependent on whether they are market or non-market conditions. As there are no set timelines in place to when the two respective conditions will be met, they are considered non-market conditions and therefore not allowed to recognize fair value.

Option grants for the year ended December 31, 2020

On May 31, 2020, the Company granted 5,000,000 options to the Chairman of its advisory board at an exercise price of \$0.11, expiring on May 31, 2025. The options vested immediately on grant. The Company also granted 500,000 options to a consultant under the same terms and expiry. The options were valued using Black-Scholes with the following assumptions: expected volatility of 126% based on comparable companies, expected dividend yield of 0%, risk-free interest rate of 0.39%, forfeiture rate of 0% and an expected life of five years. The grant date fair value attributable to these options of \$509,858 was recorded as share-based compensation in connection with the vesting of options during the year ended December 31, 2020.

On August 31, 2020, the Company granted 3,000,000 options to the CEO at an exercise price of \$0.05, expiring on August 31, 2025. The options vested immediately on grant. The Company also granted 5,500,000 options to its other officers and directors under the same exercise price and expiry, of which these options vest in one-third increments after six months, 12 months and 18 months until fully vested. The options were valued using Black-Scholes with the following assumptions: expected volatility of 124% based on comparable companies, expected dividend yield of 0%, risk-free interest rate of 0.40%, forfeiture rate of 0% and an expected life of five years. The grant date fair value attributable to these options was \$239,501, of which \$148,157 was recorded as share-based compensation in connection with the vesting of these options during the year ended December 31, 2020.

On December 8, 2020, the Company granted 1,000,000 options to a consultant at an exercise price of \$0.06, expiring on December 8, 2025. The options vested immediately on grant. The options were valued using Black-Scholes with the following assumptions: expected volatility of 126% based on comparable companies, expected dividend yield of 0%, risk-free interest rate of 0.47%, forfeiture rate of 0% and an expected life of five years. The grant date fair value attributable to these options of \$50,185 was recorded as share-based compensation in connection with the vesting of options during the year ended December 31, 2020.

During the year ended December 31, 2020, the Company also recorded stock-based compensation of \$3,615 in connection with the vesting of options which were granted prior to 2020.

The following table summarizes information of stock options outstanding and exercisable as at December 31, 2020:

Date of expiry	Number of options outstanding	Number of options exercisable	Exercise price	Weighted average remaining contractual life
	#	#	\$	Years
January 17, 2021	350,000	350,000	0.235	0.05
May 24, 2021	100,000	100,000	0.22	0.39
May 28, 2021	600,000	475,000	0.22	0.41
September 24, 2021	300,000	300,000	0.31	0.73
May 31, 2025	5,500,000	5,500,000	0.11	4.42
August 31, 2025	8,500,000	3,000,000	0.05	4.67
December 8, 2025	1,000,000	1,000,000	0.06	4.94
	16,350,000	10,725,000	0.09	4.25

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

20. Reserve for Warrants

The following summarizes the warrant activity for the years ended December 31, 2020 and 2019:

	December 31, 2020		December 31, 2019	
	Number of warrants	Weighted average exercise price	Number of warrants	Weighted Average exercise price
	#	\$	#	\$
Outstanding, beginning of year	25,213,698	0.30	7,012,172	0.41
Issued from business acquisition	35,678,400	0.05	-	-
Issued from share exchange agreement	8,400,000	0.13	813,743	0.22
Issued from share exchange agreement	933,333	0.08	-	-
Issued from conversion of debentures	22,150,000	0.05	-	-
Issued from conversion of replacement debentures	1,348,023	0.05	-	-
Issued from private placement of units	2,666,667	0.08	5,869,159	0.25
Issued from offering of subscription receipts	-	-	12,280,912	0.28
Issued from debt settlement units	7,218,545	0.07	-	-
Exercised	(28,864,840)	0.05	(254,125)	0.15
Expired	(1,052,996)	0.20	(428,163)	1.00
Expired	(2,301,873)	0.75	(80,000)	0.60
Expired	(78,015)	0.49	-	-
Expired	(2,350,000)	0.15	-	-
Expired	(467,000)	0.10	-	-
Outstanding, end of year	68,493,942	0.12	25,213,698	0.30

Warrant issuances for the year ended December 31, 2019

On January 10, 2019, the Company issued 5,746,999 warrants in conjunction with the Private Placement, as disclosed in Note 18(a). Each warrant is exercisable at \$0.25 to purchase one common share of the Company for 24 months after closing of the Private Placement. The grant date fair value of the warrants issued was estimated to be \$243,264 using Black-Scholes with the following assumptions: expected volatility of 77% based on comparable companies, expected dividend yield of 0%, risk-free interest rate of 1.91% and an expected life of two years.

In connection with the Private Placement, 122,160 Finder's Warrants were issued as compensation. The Finder's Warrants are exercisable at \$0.25 to purchase one common share of the Company. The Finder's Warrants are exercisable for a period of two years. The grant date fair value of the Finder's Warrants issued was estimated to be \$7,224 using Black-Scholes with the following assumptions: market price of \$0.18, expected volatility of 77% based on comparable companies, expected dividend yield of 0%, risk-free interest rate of 1.91% and an expected life of two years.

On February 27, 2019, the Company closed Tranche 1 of the Offering of 8,726,954 Subscription Receipts, as disclosed in Note 18(c) and issued 4,363,479 Warrants. Each Warrant is exercisable at \$0.28 into one common share of the Company for a period of 24 months from the Escrow Release Date. On May 9, 2019, the Company satisfied all Escrow Release Conditions. The grant date fair value of the Warrants issued was estimated to be \$268,280 using Black-Scholes with the following assumptions: expected volatility of 77% based on comparable companies, expected dividend yield of 0%, risk-free interest rate of 1.58% and an expected life of two years.

In connection with Tranche 1 of the Offering, 610,888 Finder's Warrants in the form of Subscription Receipt were issued as compensation. The Finder's Warrants entitles the holder to receive one unit of the Company consisting of one common share and one-half (1/2) of a Warrant, with each Warrant exercisable at \$0.28 into one common share of the Company for a period of 24 months from the date of closing of the Offering. The grant date fair value of the Finder's Warrants issued was estimated to be \$122,178 using Black-Scholes with the following assumptions: market price of \$0.20, expected volatility of 77% based on comparable companies, expected dividend yield of 0%, risk-free interest rate of 1.58% and an expected life of two years.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

20. Reserve for Warrants (continued)

Warrant issuances for the year ended December 31, 2019 (continued)

On April 17, 2019, the Company closed Tranche 2 of the Offering of 12,818,500 Subscription Receipts and issued 6,409,250 Warrants under the same terms as Tranche 1 of the Offering. Each Warrant is exercisable at \$0.28 into one common share of the Company for a period of 24 months from the Escrow Release Date, which was May 9, 2019. The grant date fair value of the Warrants issued was estimated to be \$394,060 using Black-Scholes with the following assumptions: expected volatility of 77% based on comparable companies, expected dividend yield of 0%, risk-free interest rate of 1.58% and an expected life of two years.

In connection with Tranche 2 of the Offering, 897,295 Finder's Warrants in the form of Subscription Receipt were issued as compensation to the Agents. The Finder's Warrants will entitle the holder to receive one unit of the Company consisting of one common share and one-half (1/2) of a Warrant, with each Warrant exercisable at \$0.28 into one common share of the Company for a period of 24 months from the date of closing of the Offering. The grant date fair value of the Finder's Warrants issued was estimated to be \$179,459 using Black-Scholes with the following assumptions: market price of \$0.20, expected volatility of 77% based on comparable companies, expected dividend yield of 0%, risk-free interest rate of 1.58% and an expected life of two years.

On April 17, 2019, the Company entered into the Share Exchange Agreement with FSD. In connection to the Share Exchange, 813,743 compensation options (the "Compensation Options") were issued to the Agent as corporate finance and structuring fees. The grant date fair value of the Compensation Options issued was estimated to be \$81,264 using Black-Scholes with the following assumptions: share price of \$0.23, expected volatility of 77% based on comparable companies, expected dividend yield of 0%, risk-free interest rate of 1.66% and an expected life of two years. The grant date fair value of the Compensation Options was recorded as share-based payments during the year ended December 31, 2019.

Warrant issuances for the year ended December 31, 2020

On June 15, 2020, the Company issued 32,200,400 warrants to former warrant holders of Super Smart on completion of the Super Smart Transaction and 3,478,400 finders' options (see Note 5)

During the year ended December 31, 2020, a principal amount of \$2,215,000 of the Pharmadrug Debentures were converted into 44,300,000 Units, where 22,150,000 Warrants exercisable at \$0.05 were issued (see Note 17(c)).

On July 16, 2020, the Company issued 8,400,000 Warrants exercisable at \$0.13 and 933,333 Warrants exercisable at \$0.08, respective, in pursuant to the RLH Share Exchange (see Notes 10 and 18(n)). All these Warrants are exercisable into one common share of the Company for 48 months from issuance.

On July 16, 2020, the Company also issued 2,666,667 Warrants for RLH's subscription of Units for proceeds of \$200,000 (see Note 18(o)). Each Warrant is exercisable at \$0.08 into one common share of the Company for a period of 48 months from issuance. The grant date fair value of the Warrants issued was estimated to be \$89,506 using Black-Scholes with the following assumptions: expected volatility of 146% based on comparable companies, expected dividend yield of 0%, risk-free interest rate of 0.31% and an expected life of four years.

On July 17, 2020, the Company issued 7,218,545 Warrants as part of the settlement of the total outstanding balance owing to the Former COO under the Notes, and other total obligations of \$452,250 (see Note 18(p)). Each Warrant is exercisable into one common share of the Company at \$0.07 per share at any time on or before July 17, 2023.

On December 18, 2020, the Company issued 1,348,023 Warrants as a result of the conversion of \$134,802 of principal of the Replacement Debentures at the conversion price of \$0.05 (see Note 18(r)). Each warrant is exercisable at \$0.05 to purchase one common share of the Company up to July 17, 2023.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

20. Reserve for Warrants (continued)

The following table summarizes information of warrants outstanding as at December 31, 2020:

Date of expiry	Number of warrants outstanding	Exercise price	Weighted average remaining contractual life
	#	\$	Years
January 10, 2021	5,869,159	0.25	0.03
April 17, 2021	813,743	0.22	0.29
May 9, 2021	12,280,912	0.28	0.35
June 12, 2023	10,618,560	0.05	2.45
June 15, 2023	18,345,000	0.05	2.45
July 17, 2023	7,218,545	0.07	2.54
July 17, 2023	1,348,023	0.05	2.54
July 16, 2024	3,600,000	0.08	3.54
July 16, 2024	8,400,000	0.13	3.54
	68,493,942	0.12	2.04

21. Basic and Diluted Loss per Share

The calculations of basic and diluted EPS for the year ended December 31, 2020 were based on the net loss of \$5,513,552 (2019 – net loss of \$6,539,075) and the weighted average number of basic common shares outstanding of 142,456,439 (2019 – 70,113,432) and diluted common shares of 181,917,934 (2019 – 70,113,432).

The details of the computation of basic and diluted loss per share are as follows:

	2020	2019
	\$	\$
Net Loss	(5,427,615)	(6,539,075)
	#	#
Basic weighted-average number of shares outstanding	142,456,439	70,113,432
Assumed conversion of dilutive stock options and warrants	-	-
Diluted weighted-average number of shares outstanding	142,456,439	70,113,432
	\$	\$
Basic loss per share	(0.038)	(0.093)
Diluted loss per share	(0.038)	(0.093)

22. Key Management Personnel Compensation and Related Party Transactions

Key management includes the Company's directors, officers and any employees with authority and responsibility for planning, directing and controlling the activities of an entity, directly or indirectly.

Key management personnel compensation

The remuneration of directors and other members of key management personnel during the years ended December 31, 2020 and 2019 were as follows:

	2020	2019
	\$	\$
Management salaries and consulting fees	40,000	240,000
Professional fees	90,000	134,960
Share-based compensation	211,157	16,421
	341,157	391,381

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

22. Key Management Personnel Compensation and Related Party Transactions (continued)

Key management personnel compensation (continued)

During the year ended December 31, 2020, Daniel Cohen, the CEO of the Company, did not charge the Company for consulting services provided to the Company (2019 – \$90,000). As at December 31, 2020, no balance was owed to the CEO (December 31, 2019 – \$65,606, included in accounts payable and accrued liabilities).

Effective September 1, 2020, the Company and the CEO also entered into an executive agreement, whereas the Company agreed to pay an annual base salary of \$120,000 for CEO services. The annual base salary shall be increased to \$180,000, exclusive of bonuses, benefits and other compensation, once the Company has raised a minimum of \$1,500,000. During the year ended December 31, 2020, the Company recorded management salaries of \$40,000 in relation to the CEO's employment compensation.

During the year ended December 31, 2020, Howard Brass, the Former COO, also did not charge the Company for consulting services provided to the Company up to his resignation on May 21, 2020 (2019 – \$100,000). As at December 31, 2020, no balance was owed to the Former COO (December 31, 2019 – \$62,150, included in accounts payable and accrued liabilities).

During the year ended December 31, 2020, Branson Corporate Services Ltd. ("Branson"), where Keith Li, the Chief Financial Officer ("CFO") and Corporate Secretary of the Company is employed, charged fees of \$90,000 (2019 – \$134,960, including billings on certain services provided from 2017 and up to the RTO Transaction on 2018), for providing CFO services to the Company, as well as other accounting and administrative services. As at December 31, 2020, \$39,550 (December 31, 2019 – \$70,620) owing to Branson was included in accounts payable and accrued liabilities. The amount outstanding is unsecured, non-interest bearing and due on demand.

During the year ended December 31, 2019, David Posner, the former Chairman of the Company, charged consulting fees of \$50,000 for services provided to the Company. As at December 31, 2020, no balance was owed to the former Chairman (December 31, 2019 – \$77,950, included in accounts payable and accrued liabilities).

Share-based compensation

On January 17, 2019, the Company granted 200,000 options to a former director of Pharmadrug. The options vested immediately on grant, and the grant date fair value of \$16,421 attributable to these options was recorded as share-based compensation during year ended December 31, 2019. On August 14, 2019, these options were cancelled.

On August 31, 2020, the Company granted 3,000,000 options to the CEO at an exercise price of \$0.05, expiring on August 31, 2025. The options vested immediately on grant. The Company also granted 5,500,000 options to its other officers and directors under the same terms and expiry, of which these options vest in one-third increments after six months, 12 months and 18 months until fully vested. The grant date fair value attributable to these options was \$239,501, of which \$148,157 was recorded as share-based payments in connection with the vesting of these options during the year ended December 31, 2020.

On August 31, 2020, the Company issued 1,300,000 common shares to an entity controlled by the CEO of the Company, and 500,000 common shares to the Former COO, respectively, as compensation as stipulated by their respective consulting agreement with Pharmadrug. The common shares valued at \$63,000 was included in share-based payments during the year ended December 31, 2020.

Restructuring on debts with related parties

On July 17, 2020, the Company completed the Restructuring which also involved amounts previously due to certain of its officers.

Indebtedness exchanged as part of the aggregate of \$1,005,620 principal amount of Replacement Debentures include:

- A balance of \$269,604 owed to the CEO, comprised of a \$200,000 principal amount and accrued interest of \$69,604 under the Notes (see Note 15); and
- A balance of \$233,206 owed to the CEO, comprised of a \$200,000 principal amount and accrued interest of \$22,815 under the Unsecured Debentures (see Note 17(b)).

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

22. Key Management Personnel Compensation and Related Party Transactions (continued)

Restructuring on debts with related parties (continued)

Indebtedness settled as part of the issuance of 14,437,090 Units at a deemed price of \$0.05 per Unit (see Note 18) include:

- A balance of \$62,150 owed to the CEO for services provided under the terms of his consulting agreement.
- A balance of \$269,604 owed to the CEO, comprised of a \$200,000 principal amount and accrued interest of \$69,604 under the Notes (see Note 15).
- A balance of \$62,150 owed to the Former COO for services provided under the terms of his consulting agreement; and
- A balance of \$77,950 owed to the former Chairman for consulting services previously provided to the Company.

23. Non-Controlling Interest

On completion of the Pharmadrug Acquisition, the 20% interest attributable to Anquor is presented as “non-controlling interest” within shareholders’ equity on the consolidated statements of financial position. For the year ended December 31, 2020, the Company recorded a net loss of \$277,334 (2019 – net loss of \$249,239) attributable to the non-controlling interest.

24. Income Taxes

The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 26.5% (2019 – 26.5%) to the effective tax rate is as follows:

	2020	2019
	\$	\$
Net loss before recovery of income taxes provision:	(5,902,627)	(6,981,823)
Expected income tax recovery	(1,564,196)	(1,850,183)
Difference in foreign tax rates	(85,817)	(53,934)
Tax rate changes and other adjustments	90,769	(64,357)
Share-based compensation and non-deductible expenses	838,558	311,712
Change in tax benefits not recognized	245,674	1,214,014
Income tax recovery	(475,012)	(422,748)

Deferred tax

The following table summarizes the components of deferred tax:

	2020	2019
	\$	\$
<u>Deferred Tax Assets</u>		
Non-capital losses carried forward - Germany	328,505	152,341
Non-capital losses carried forward – Canada	87,454	-
Capital losses carried forward – Canada	48,161	-
Lease payable	31,931	29,537
<u>Deferred Tax Liabilities</u>		
Other investments	(113,578)	-
Intangibles	(1,342,239)	(1,625,918)
Property and equipment, including ROU assets	(14,613)	(27,388)
Convertible debentures	(22,037)	-
Movement in foreign exchange	-	1,967
Net deferred tax liabilities	(996,415)	(1,469,461)

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

24. Income Taxes (continued)

Deferred tax assets and liabilities have been offset where they relate to income taxes levied by the same taxation authority and the Company has the legal right and intent to offset.

Movements in net deferred tax liabilities:

	2020	2019
	\$	\$
Balance, beginning of year	(1,469,461)	-
Recognized in business combination	-	(1,916,176)
Recognized in profit or loss	475,012	442,748
Effect of foreign exchange	(1,966)	1,967
Balance, end of year	(996,415)	(1,469,461)

Unrecognized deferred tax assets

Deferred taxes are provided as a result of temporary differences that arise due to the differences between the income tax values and the carrying amount of assets and liabilities. Deferred tax assets have not been recognized in respect of the following deductible temporary differences:

	2020	2019
	\$	\$
Share issuance costs	415,636	588,153
Net operating losses carried forward – U.S.	574,408	602,642
Non-capital losses carried forward – Canada	7,008,067	5,721,056
Net capital loss carried forward – Canada	-	812,642
Investments	-	397,571
Other temporary differences	148,810	162,443

The Canadian non-capital loss carry-forwards expire as noted in the table below.

Share issuance and financing costs will be fully amortized in 2023. The remaining deductible temporary differences may be carried forward indefinitely.

Deferred tax assets have not been recognized in respect of these items because it is not probable that future taxable profit will be available against which the group can utilize the benefits therefrom.

The Company's Canadian non-capital income tax losses expire as follows:

	\$
2037	590,888
2038	1,117,865
2039	3,684,273
2040	1,615,041
	7,008,067

The Company's U.S. net operating losses expire as follows:

	\$
2036	42,655
2037	272,290
Indefinite	259,463
	574,408

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

25. Capital Management

The Company manages its capital structure and adjusts it, based on the funds available to the Company, in order to support the development of its planned business activities. The Board does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. In order to carry out the planned business activities and pay for administrative costs, the Company will spend its existing working capital and raise additional funds as needed. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.

The Company considers its capital to be shareholders' equity, which is comprised of share capital, equity component of convertible debentures, reserves for share-based payments and warrants, accumulated other comprehensive loss and accumulated deficit. As at December 31, 2020, the Company's capital consisted of an equity attributable to the shareholders of Pharmadrug Inc. of \$9,657,057 (December 31, 2019 – equity attributable to the shareholders of Pharmadrug Inc. of \$2,977,966).

The Company's objective when managing capital is to obtain adequate levels of funding to support its business activities, to obtain corporate and administrative functions necessary to support organizational functioning and obtain sufficient funding to further the development of its business. The Company raises capital, as necessary, to meet its needs and take advantage of perceived opportunities and, therefore, does not have a numeric target for its capital structure. Funds are primarily secured through equity capital raised by way of private placements and issuance of convertible debentures. There can be no assurance that the Company will be able to continue raising capital in this manner.

The Company is not subject to externally imposed capital requirements.

26. Financial Risks

Credit risk

Credit risk is the risk of loss associated with counterparty's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash, other receivables and note receivable, which expose the Company to credit risk should the borrower default on maturity of the instruments. Cash is held with reputable chartered banks in Canada and Germany, and in trust with the Company's legal counsel. Management believes that the credit risk concentration with respect to financial instruments included in cash and other receivables is minimal. For the year ended December 31, 2020 the company recorded a reversal of ECL on the Empower loan receivable of \$155,614 (Note 9) and an ECL on trade receivables of \$2,904 which are included in reversal (allowance) on ECL in the consolidated statements of loss and comprehensive loss.

Liquidity risk

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if the Company's access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or related to matters specific to the Company. The Company generates cash flow primarily from its financing activities.

As at December 31, 2020, the Company had a cash balance of \$2,134,866 (December 31, 2019 – \$73,677) and liquid investments valued at \$2,269,504 (December 31, 2019 – \$440,052), to settle current liabilities of \$619,303 (December 31, 2019 – \$4,320,092).

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

26. Financial Risks (continued)

Liquidity risk (continued)

As at December 31, 2020, the Company had the following contractual obligations:

	Less than 1 year	1 to 3 years	3 to 5 years	Total
	\$	\$	\$	\$
Accounts payable and accrued	562,130	-	-	562,130
Lease liabilities	94,060	58,249	32,351	184,660
Provisions	91,270	-	-	91,270
Convertible debentures	-	1,033,082	-	1,033,082
Total	747,460	1,091,331	32,351	1,871,142

The Company manages liquidity risk by maintaining adequate cash reserves and by continuously monitoring forecast and actual cash flows for a rolling period of 12 months to identify financial requirements. Where insufficient liquidity may exist, the Company may pursue various debt and equity instruments for short or long-term financing of its operations.

During the year ended December 31, 2020, the Company completed the Restructuring in order to improve its solvency and liquidity position. With the Restructuring in place, management believes there is sufficient capital to meet short-term business obligations, after taking into account cash flows requirements from operations and the Company's cash position as at year-end.

COVID-19

In December 2019, COVID-19 surfaced in Wuhan, China. The World Health Organization declared a global emergency on January 30, 2020 with respect to the outbreak then characterized it as a pandemic on March 11, 2020. The outbreak has spread throughout Europe and the Middle East and there have been cases of COVID-19 in Canada and the U.S., and has continued to cause companies and various international jurisdictions to impose restrictions, such as quarantines, closures, cancellations and travel restrictions. The duration of the business disruptions internationally and related financial impact to the global economy remains highly uncertain at this time, as COVID-19 continues to evolve.

The Company's German operations had been impacted by limited supply of cannabis products caused by shipment delays from the Netherlands, but management expects the situation to improve once lockdown restrictions will be lifted with vaccine roll-out. Ultimately, the extent to which the COVID-19 pandemic impacts the Company's financial results will depend on future developments, which remain highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the COVID-19 pandemic and actions taken to contain it or its impact, among others. These uncertainties arise from the inability to predict the ultimate geographic spread of the disease, and the duration of the outbreak, including the duration of travel restrictions, business closures or disruptions, and quarantine/isolation measures that are currently, or may be put in place by Canada, Germany, the Netherlands and other countries to fight the virus. While the extent of the impact remains unknown, the Company anticipates this outbreak may cause supply chain disruptions, and increased government regulations, all of which may negatively impact the Company's business and financial condition.

Market risk

Market risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in market prices. The value of the financial instruments can be affected by changes in interest rates, foreign exchange rates, and equity and commodity prices. The Company is exposed to market risk in trading its investments and unfavorable market conditions could result in dispositions of investments at less than favorable prices. A 1% change in closing trade price of the Company's other investments would impact net income or loss by approximately \$22,700 based upon balances as at December 31, 2020.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

26. Financial Risks (continued)

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's loans payable, notes payable and convertible debentures have fixed interest rates. As at December 31, 2020, the Company had no hedging agreements in place with respect to floating interest rates.

Foreign exchange risk

Foreign exchange risk is the risk that the Company will be subject to foreign currency fluctuations in satisfying obligations related to its foreign activities. The Company has operations in Europe where there are financial instruments and transactions denominated in foreign currencies, notably in EUR. The Company's primary exposure to foreign exchange risk is that transactions denominated in EUR may expose the Company to the risk of exchange rate fluctuations.

Fair value

Fair value estimates of financial instruments are made at a specific point in time based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values. The Company's financial instruments consist of cash, other receivables, note receivable, other investments accounts payables and accrued liabilities, loans payable, notes payable, lease liabilities and convertible debentures.

The fair value of cash, receivables, note receivable, other investments, accounts payables and accrued liabilities, loans payable and notes payable, are approximately equal to their carrying value due to their short-term nature. The fair values of the lease liabilities and convertible debentures approximate their carrying amounts as they were measured taking into consideration comparable instruments with similar risks in determining the rates at which to discount their amount in applying their respective measurement models.

The Company classifies fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 – Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 – Inputs for the asset or liability that are not based on observable market data (unobservable inputs).

	Level 1	Level 2	Level 3	Total
	\$	\$	\$	\$
Other investments	1,293,939	975,565	-	2,269,504

As at December 31, 2020, the Company's financial instruments carried at fair value consisted of its other investments, which have been classified as Level 1 and Level 2 (for investments in warrants securities). There were no other transfers between Levels 2 and 3 for recurring fair value measurements during the year ended December 31, 2020.

27. Contingencies

The Company's cannabis operations are subject to a variety of local regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations in that specific state or local jurisdiction. In Germany, the legalization of medical cannabis in March 2017 gave rise to a formal medical cannabis program nationwide. However, Germany does not currently have a legally permissible adult-use, or recreational cannabis market. While management believes that the Company is in compliance with applicable local regulations as at December 31, 2020, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties, or restrictions in the future.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

27. Contingencies (continued)

The Company may, from time to time, be subject to various administrative, regulatory, and other legal proceedings arising in the ordinary course of business. Liabilities associated with legal proceedings are recorded when: (i) the liabilities are a result of a past event, (ii) it is probable that an outflow of resources will be required to settle the obligations, and (iii) a reliable estimate can be made of the amount of obligation.

As at December 31, 2020, the Company had the following claims:

On August 20, 2019, THoR Beteiligungen GmbH (“THoR”) incorrectly transferred an amount of €6,804 to Pharmadrug GmbH’s business account and subsequently demanded its repayment. On October 22, 2019, Pharmadrug GmbH declared that the Company would offset this amount against a counterclaim against THoR, which subsequently issued a notice of assignment, according to which the claim had been assigned to Pharmadrug International GmbH (“Pharmadrug International”) on September 27, 2019. Pharmadrug International has since filed a claim for repayment of a mismatch transfer against Pharmadrug GmbH for the same amount.

On February 21, 2020, Thor Investments GmbH (“Thor Investments”) filed a lawsuit with Pharmadrug GmbH for a repayment of a loan in the amount of €34,222 plus interest. The loan with Thor Investments dates back to March 2019.

As at December 31, 2020, the Company had recorded a provision of approximately \$91,270 (€58,747) for the estimated potential damages it is expected to pay out on the above claims.

28. Commitments

On July 21, 2020, the Company entered into a supply agreement (the “NMC Supply Agreement”) with Natural MedCo Ltd. (“NMC”), a Canadian Licensed Producer of medical cannabis and a wholly-owned subsidiary of Eve & Co Incorporated, for bulk and finished EuGMP medical cannabis. Pursuant to the NMC Supply Agreement, the Company is required to purchase and import into Germany between 250 to 500 kg of cannabis flower on a bulk basis. The NMC Supply Agreement shall remain in force and effect for a period of three years, and will automatically renew for additional successive two-year terms.

On January 4, 2021, the Company entered into a supply agreement with a Canadian-based multinational cannabis company for EUGMP certified medical cannabis. The supply is already registered and approved for sale in the German market. Pursuant to the supply agreement, Pharmadrug GmbH will purchase branded medical cannabis from the supplier’s German subsidiary. Pharmadrug GmbH has already received regulatory approval to distribute the cannabis and the product has been added to their license. The flower will be imported into Germany by the global supplier and sold under the supplier's medical cannabis brand.

29. Segmented Information

As at December 31, 2020, the Company’s operations comprise of the corporate division in Canada, the distribution operations of medical cannabis in Germany, and the retail Smart Shop in the Netherlands. As at and for the years ended December 31, 2020 and 2019, the breakdown between operations in Canada, Germany and the Netherlands are as follows:

Year ended December 31, 2020

	Canada	Germany	Netherlands	Total
	\$	\$	\$	\$
Non-current assets	2,269,504	8,962,572	16,997	11,249,073
Revenue	-	677,531	6,139	683,671

Year ended December 31, 2019

	Canada	Germany	Total
	\$	\$	\$
Non-current assets	440,052	9,597,499	10,037,551
Revenue	-	610,576	610,576

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

30. Finance Costs

Finance costs are composed of the following:

	\$
Interest on settled convertible debentures (Note 17(c))	41,201
Interest on notes payable (Note 15)	75,652
Interest on Private Loan (Note 10)	8,897
Interest on Bridge Loan Facility (Note 10)	92,017
Interest on Replacement Debentures (Note 17(d))	71,668
Interest on Pharmadrug Debentures (Note 17(c))	62,135
Other interest revenue	(30,277)
	321,293

31. Subsequent Events

Sairiyo Acquisition

On January 24, 2021, the Company entered into a share exchange agreement (the “Agreement”) to acquire Sairiyo Therapeutics Inc. (“Sairiyo”), a biotechnology company focused on developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases.

On February 2, 2021, the Company completed the acquisition of Sairiyo. Under the terms of the Agreement, the Company acquired all of the issued and outstanding shares of Sairiyo in consideration for the issuance of an aggregate of 75,000,000 Units of Pharmadrug. Each Unit is comprised of one common share and one Warrant of Pharmadrug. Each Warrant entitles the holder thereof to acquire one common share in the capital of Pharmadrug at any time on or before the August 2, 2022 at an exercise price of \$0.10 per share.

The Company is currently working to finalize the accounting related to the acquisition of Sairiyo.

Shares, options and warrants

On January 10, 2021, 5,869,159 warrants exercisable at \$0.25, expired unexercised.

On January 17, 2021, 350,000 options exercisable at \$0.235, expired unexercised.

On February 4, 2021, the Company granted 4,250,000 options to its officers and directors. The options are exercisable at a price of \$0.085 per common share for a period of five years. 4,250,000 options granted to officers and directors will vest in one-third increments after three months, six months and 12 months until fully vested. The Company also granted 950,000 options to consultants under the same exercise price and expiry, which vested immediately on grant.

On February 17, 2021, the Company issued 850,000 common shares as a result of the exercises of 850,000 stock options for cash proceeds of \$72,250.

On April 17, 2021, 813,743 Compensation Options previously issued in connection to the Share Exchange with FSD exercisable at \$0.22, expired unexercised.

On May 9, 2021, 12,280,912 warrants exercisable at \$0.28, expired unexercised.

On May 12, 2021, the Company granted 2,000,000 options to an officer. The options are exercisable at a price of \$0.09 per common share for a period of five years. 500,000 options vested immediately on grant; 750,000 options will vest six months from date of issuance, and the remaining 750,000 options will vest 12 months from date of issuance.

On May 24, 2021, 100,000 options exercisable at \$0.22, expired unexercised.

PHARMADRUG INC.

Notes to the Amended and Restated Consolidated Financial Statements
For the Years Ended December 31, 2020 and 2019
(Expressed in Canadian Dollars)

31. Subsequent Events (continued)

Subsequent to December 31, 2020, the remaining principal amount of \$285,000 of the Pharmadrug Debentures was converted into 5,700,000 Units of the Company at a price of \$0.05 per share.

Subsequent to December 31, 2020, the Company issued 17,134,200 common shares as a result of the exercises of 17,134,200 Warrants for cash proceeds of \$856,710.